Last Updated: 1/2/2007CURRICULUM VITAE

PERSONAL DATA

Name: Norman L. FosterBirth Date: July 27, 1951Place of Birth: Jacksonville, Illinois, U.S.A.

EDUCATION, CERTIFICATES and LICENSURE

Baccalaureate Degree: 1969 – 1973 BA Biology & Chemistry, summa cum laude, MacMurray College, Jacksonville, IL

Advanced Degree: 1973 – 1977 MD Washington University School of Medicine, St. Louis, MOPostdoctoral Training: 1981 – 1984 Fellow Experimental Therapeutics Branch, National Institute of

Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, MD

1978 – 1981 Resident Department of Neurology, University of Utah Hospitals, Salt Lake City, UT

1977 – 1978 Intern Straight Medicine, Jewish Hospital of St. Louis, Washington University Medical Center, St. Louis, MO

Licenses/Certifications: 2005 – present State Medical License, Utah (#163537-1205, #163537-8905)1984 – present State Medical License, Michigan (#4301047175)1983 – present Neurology Diplomate, American Board of Neurology &

Psychiatry1979 (inactive) State Medical License, Utah (#6092)

PROFESSIONAL EXPERIENCE

Full-Time Positions

8/2005 – present Director, Center for Alzheimer’s Care, Imaging & Research, University of Utah, Salt Lake City, UT

8/2005 – present Professor, Department of Neurology, University of Utah, Salt Lake City, UT

8/2005 – present Senior Investigator, The Brain Institute, University of Utah, Salt Lake City, UT

8/2005 – present Adjunct Professor, Department of Neurology, University of Michigan, Ann Arbor, MI

9/2003 – 8/2005 Research Professor, Institute of Gerontology, University of Michigan, Ann Arbor, MI

9/1998 – 8/2005 Professor, Department of Neurology, University of Michigan, Ann Arbor, MI

7/1984 – 2005 Attending Staff Physician, University Hospital, University of Michigan, Ann Arbor, MI

9/1998 – 8/2003 Senior Research Scientist, Institute of Gerontology, University of Michigan, Ann Arbor, MI

7/1985 – 8/2002 Consultant and Attending Physician, Veterans Administration Hospital, Ann Arbor, MI

7/1984 – 8/1991 Assistant Professor, Department of Neurology, University of Michigan, Ann Arbor, MI

9/1997 – 8/1998 Senior Associate Research Scientist, Institute of Gerontology, University of Michigan, Ann Arbor, MI

9/1995 – 8/1997 Associate Research Scientist, Institute of Gerontology, University of Michigan, Ann Arbor, MI

9/1991 – 8/1998 Associate Professor, Department of Neurology, University of Michigan, Ann Arbor, MI

7/1983 – 6/1984 Attending Physician, Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, MD

7/1977 – 6/1978 Assistant in Medicine, Washington University, St. Louis, MO

EDITORIAL EXPERIENCE

Periodical Reviews

Alzheimer Disease and Associated Disorders: 2002American Journal of Geriatric Psychiatry: 2004, 2006American Journal of Managed Care: 2003

Annals of Neurology: 1986 – 2003Archives of Neurology: 1998 – 2006Brain: 2004 – 2006Clinical Neuropharmacology: 2005European Journal of Neurology: 2004Expert Review of Neurotherapeutics: 2003Human Brain Mapping: 2005 Journal of Geriatric Psychiatry and Neurology: 1997 – presentJournal of Gerontology, Part B Psychological Science and Social Science: 2000Journal of Neuroophthamalogy: 2005Journal of the American Geriatrics Society: 1985, 1995 – 2000Journal of the Neurological Sciences: 1998 – 2000, 2002 – 2005Neurobiology of Aging: 1983, 2004Neuroimage: 2003Neurology: 1987 – 2002, 2004New England Journal of Medicine: 2000, 2005Nicotine and Tobacco Research: 2002Psychiatry Research Neuroimaging: 2003Scandinavian Journal of Gastroenterology: 2002Sleep: 2001Telemedicine Journal and Electronic Health: 2002The Clinical Neuropsychologist: 1990

Book Reviews

Neurosurgery: 16:119, 1985

RESEARCH AWARDS

Current Research Support

Dates of Support Grant Information and Sponsor Role

11/1/06 -- 10/31/07 Early Detection of Alzheimer’s Disease in a Community Population Using Longitudinal Cognitive Assessment (Early AD Detection). Anonymous Foundation.

P.I.

7/1/06 -- 6/30/10 Comprehensive Program to Strengthen Physician’s Training in Geriatrics. Donald W. Reynolds Foundation.

Co-Investigator (PI: Supiano)

10/1/04 – 8/31/09 Alzheimer’s Disease Neuroimaging Initiative (ADNI) (U01 AG024904). NIA.

P.I.

7/1/03 – 7/31/06 Pilot Collaborative PET Imaging Trial (R01-AG022394). NIA. P.I.

7/1/02 – 6/30/07 Training Grant: Training in Clinical and Basic Neuroscience (T32-NS07222). National Institutes of Health, NINDS.

Co-Investigator

Pending Research Support

Dates of Support Grant Information and Sponsor Role

7/1/07 -- 6/30/12 Ancillary Studies to the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (PA-04-158). NIH.

Co-Investigator (PI: Whitaker)

Completed Research Support

Dates of Support Grant Information and Sponsor Role

7/1/01 – 6/30/05 Alzheimer’s Disease Cooperative Study (U01-AG10483). NIA. P.I.

7/1/96 – 6/30/01 Grant Extension P.I.

Subprojects:

7/1/01 – 8/31/02 NSAID Trial. P.I.

4/1/99 – 7/30/04 MCI Trial: A randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of vitamin E and donepezil HCl (Aricept) to delay clinical progression from mild cognitive impairment (MCI) to Alzheimer’s disease (AD).

P.I.

3/1/94 – 9/30/96 Haloperidol, Trazadone, and Behavior Management P.I.

Techniques in Alzheimer’s Disease Patients with Disruptive Agitated Behaviors: A Controlled Clinical Trial.

7/1/93 – 6/30/95 A Multicenter Evaluation of New Treatment Efficacy Instruments for AD Clinical Trials.

P.I.

6/1/92 – 6/30/95 A Double-Blind, Placebo-Controlled Multicenter Study to Examine the Safety and Efficacy of Selegiline and alpha-Tocopherol in the Treatment of Alzheimer’s Disease.

P.I.

1/1/91 – 9/30/96 Project 3: Alzheimer Disease Study Units. P.I.

7/1/01 – 6/30/05 Training Grant: Comprehensive Programs to Strengthen Physicians’ Training to Geriatrics. The Donald W Reynolds Foundation.

Co-Investigator

4/1/01 – 3/31/06 Training Grant: Identifying Cases and Costs of Dementia in the US (K08-AG19180-01). NIH, Mentored Clinical Scientist Development Award.

P.I.

10/1/00 – 6/30/03 Collaborative PET Imaging Study (extended). NIH Prime (University of Washington National Alzheimer’s Disease Coordinating Center).

P.I.

7/1/00 – 6/30/03 Training Grant: Program for Collaborative Interprofessional Team Education (CITE) at the University of Michigan. Robert Woods Johnson Foundation Grant.

Co-Investigator

5/1/00 – 4/30/05 Multidisciplinary Research Training in Aging (T32-AG00114). NIH. Co-Investigator

12/21/99 – 12/21/00

A Multicenter Randomized Double-Blind, Placebo-Controlled Study to Evaluate AIT-082 in Patients with Probable Alzheimer’s Disease of Mild to Moderate Severity (90 day treatment period plus 60 day follow-up). NeoTherapeutics, Inc. and Synapse Technologies, Inc.

Co-Investigator

12/1/99 – 11/30/00 A 30 Week, Open-label Evaluation of Donepezil Hydrochloride (E2020) in Patients with Dementia Associated with Cerebrovascular Disease (Protocol E2020-A001-309). Eisai, Inc.

Co-Investigator

7/1/99 – 5/31/00 Michigan Alzheimer Disease Research Center (P50-AG08671). NIA. P.I.

Subprojects:

6/1/99 – 5/31/05 Core B, Clinical Core (with bridging funds). P.I.

6/1/94 – 5/31/99 Core B, Clinical Core. P.I.

6/1/94 – 5/31/99 Project 2: Neuropharmacologic Challenges in Dementia.

P.I.

9/30/92 – 5/31/94 Administrative Supplement: Northern Michigan Satellite Diagnostic and Treatment Center.

P.I.

7/1/91 – 5/31/94 Administrative Supplement: Detroit Satellite Diagnostic and Treatment Center.

P.I.

10/1/89 – 9/30/94 Core A: Clinical Core. P.I.

10/1/89 – 9/30/94 Project 2: Neuropharmacologic Challenges in Dementia.

P.I.

6/1/03 – 5/31/04 Depression/HPA Axis Dysregulation Increases Alzheimer’s Risk in Mild Cognitive Impairment.

Co-Investigator

6/1/99 – 5/31/04 Core A: Administrative Core. Co-Investigator

6/1/94 – 5/31/99 Project 1: Benzodiazepine Receptors in Neurodegenerative Disease.

Co-Investigator

6/1/94 – 5/31/99 Core A: Administrative Core. Co-Investigator

10/1/89 – 9/30/94 Project 1: Motor Correlates of Dementia. Co-Investigator

7/1/97 – 6/30/02 Training Grant: Training in Clinical and Basic Neuroscience (T32-NS07222). NIH, NINDS.

Co-Investigator

7/1/97 – 5/30/01 ADCS Supplement: Vitamin E to Prevent Progression to AD. NIA. P.I.

7/1/97 – 6/30/00 Training Grant: Innovations in Health Professions Education. State of Michigan, Department of Community Health.

Co-Investigator

1/2/97 – 5/31/98 An Open-label Study to Evaluate the Safety and Efficacy of 1.5mg b.i.d. Co-Investigator

(3mg/day) through 6mg b.i.d. (12mg/day) of Exelon in Patients with Mild to Severe Probable Alzheimer’s Disease in the Community Setting (Protocol ENAB-356). Novartis Pharmaceutical Corporation.

12/1/96 – 11/30/01 Emission Computed Tomography of Local Cerebral Function (R01-NS20867). NIH, NINDS.

Co-Investigator

9/1/96 – 8/31/97 A Conference on Chromosome 17-linked Dementias (R13-AG13904). NIH.

P.I.

7/1/96 – 3/31/99 Documenting the African-American Health Care Experience in Michigan (including 1 year no cost extension). WK Kellogg Foundation.

P.I.

7/1/ 96 – 3/31/98 Grant Extension Co-Investigator

5/1/95 – 4/30/00 Training Grant: Multidisciplinary Research Training in Aging (T32-AG00114). NIA.

Co-Investigator

9/1/95 – 8/31/97 Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) (U01-AG06790). NIA.

P.I.

11/1/90 – 10/31/95 Grant Extension P.I.

6/1/95 – 12/31/97 A 52-Week, Randomized, Double-Blind, Placebo-Controlled Study of Acetyl-L-Carnitine in Patients with Age-Defined (Between 45 and 65 Years of Age) Alzheimer’s Disease (ST-94-101). Quintiles Pacific, Inc. (Sigma Tau Gamma Pharmaceuticals).

Co-Investigator

6/1/95 – 12/31/97 A Multi-center, Double-Blind, Placebo-Controlled Study of Acetyl-L-Carnitine in Patients with Age-Defined (Between 45 and 65 Years of Age) Alzheimer’s Disease (ST-94-101). Quintiles Pacific, Inc. (Sigma Tau Gamma Pharmaceuticals).

Co-Investigator

10/1/93 – 12/31/94 A Controlled Study of Ondansetron in the Treatment of Primary Degenerative Dementia of the Alzheimer Type, Protocol S3A-228. Glaxo Research Institute.

P.I.

7/1/93 – 6/30/95 Behavioral Shaping for Disruptive Behavior in Dementia (F33-NR06911). NIH, Senior National Research Service Award.

P.I.

7/1/92 – 10/1/93 The Cognex Treatment IND Program for Patients with Alzheimer’s Disease (970-58). Warner-Lambert/Parke-Davis Pharmaceutical Research Division.

P.I.

1/1/92 – 12/31/94 A Double-Blind, Placebo-Controlled, Safety, Tolerability and Efficacy Study of L-693 487 (heptylphysostigmine) following Slow Titration in Patients with Alzheimer’s Disease. Merck Sharp and Dohme Pharmaceutical Company.

P.I.

11/1/91 – 12/31/94 Open-Label Extension of Protocol 970-61 (protocol 970-62). Warner-Lambert/Parke-Davis Pharmaceutical Research Division.

P.I.

11/1/91 – 12/31/94 A Double-blind, Placebo-controlled, Parallel Group, High-Dose Study of Tacrine (CI-970) in Patients with Alzheimer’s Disease (Protocol 970-61). Warner-Lambert/Parke-Davis Pharmaceutical Research Division.

P.I.

4/1/91 – 5/31/93 Double-blind, Placebo-Controlled, Parallel Group Multi-center Study of Tacrine (CI-970) in Alzheimer’s Disease Patients (Protocol 970-26). Warner-Lambert/Parke-Davis Pharmaceutical Research Division.

P.I.

9/1/90 – 4/30/93 Effect of Idebenone and Placebo on Regional Cerebral Glucose Metabolism and Neuropsychological Performance in Patients with Alzheimer’s Disease (M89-383). Takeda-Abbott Research and Development Company (later TAP Pharmaceuticals).

P.I.

7/1/90 – 7/31/94 Neuropharmacologic Challenges in Dementia (R01-MH47144) (including 1 year no cost extension). NIH.

P.I.

6/1/90 – 10/31/92 An Open-Label, Multicenter Safety Study of Tacrine Hydrochloride (CI-970) in Alzheimer’s Disease Patients with Prior Exposure to Tacrine in a Parke-Davis Sponsored Clinical Trial (Protocol 970-15-602). Warner-Lambert/Parke-Davis Pharmaceutical Research Division.

P.I.

12/1/89 – 11/30/94 PET Study of Biochemistry and Metabolism of the CNS (P01-NS15655). NIH, NINCDS.

Co-Investigator

7/1/89 – 6/30/91 A Pilot Prospective Study of Magnetic Resonance Imaging and Positron Emission Tomography in Lupus Patients with Dementia (CRC Project #835) (M01-RR00042). University of Michigan Clinical Research Center.

Co-Investigator

7/1/89 – 9/28/89 The Role of Glutamate in Alzheimer’s Disease (R01-AG06155). NIA. Grant Extension: 4/1/86 – 3/31/89, Co-Investigator.

Co-Investigator

5/1/89 – 4/30/90 Neuropsychological Studies of Milacemide in the Treatment of Alzheimer’s Disease. G D Searle and Company.

Co-Investigator

5/1/89 – 9/1/89 Milacemide in the Treatment of Alzheimer’s Disease (NC7-88-02-033). G D Searle and Company.

P.I.

4/1/89 – 3/31/94 Emission Computed Tomography of Local Cerebral Function (R01-NS20867). NIH, NINCDS. Grant Extension: 7/1/86 – 3/31/89, Co-Investigator.

Co-Investigator

9/1/88 – 8/31/90 The Ethel and James Flinn Family Foundation Grant. The Ethel and James Flinn Family Foundation Grant.

Co-Investigator

8/10/88 – 12/31/92 A Double-Blind Placebo-Controlled Multicenter Study of Tacrine (CI-970) and Lecithin (CI-909) in Alzheimer’s Disease Patients. Warner-Lambert/Parke-Davis Pharmaceutical Research Division.

P.I.

1/1/88 – 12/31/88 SPECT and the Prognosis of Memory Loss (# 386136). Horace H Rackham Faculty Research Grant.

P.I.

5/1/87 – 4/30/88 A Double-Blind, Placebo-Controlled Multicenter Study of CI-933 in Age-Associated Memory Impairment. Warner-Lambert/Parke-Davis Company.

Co-Investigator

2/1/87 – 7/1/89 Cholinergic Agonist RS-86 in Progressive Supranuclear Palsy (CRC Project #670) (M01-RR00042). University of Michigan Clinical Research Center.

P.I.

8/1/86 – 8/1/87 A Placebo-Controlled Compassionate Plea Study of Pramiracetam in an Alzheimer Patient (Warner-Lambert Protocol #879-34). Warner-Lambert/Parke-Davis Pharmaceutical Research Division.

P.I.

2/1/86 – 6/30/90 PET Investigations of Alzheimer’s Disease (CRC Project #572) (M01-RR00042). University of Michigan Clinical Research Center.

P.I.

7/1/85 – 6/30/90 PET Investigations of Alzheimer’s Disease (K08-NS-01023). National Institute of Neurologic Disorders and Stroke. **PET Operating Committee, PET Pilot Project.

P.I.

7/1/85 – 11/30/89 PET Study of Biochemistry and Metabolism of CNS, Subproject: PET Investigations of Alzheimer’s Disease (P01-NS-15655-06S1). National Institute of Neurologic Disorders and Stroke.

P.I.

12/1/84 – 11/30/89 PET Study of Biochemistry and Metabolism of the CNS (P01-NS15655). NIH, NINCDS.

Co-Investigator

Training Grant: “A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients with Mild to Moderate Dementia of the Alzheimer’s Type (MEM-MD-10)”, Forest Pharmaceuticals

Co-Investigator

SCHOLASTIC HONORS and AWARDS

1996 – 2004 Listed in “The Best Doctors in America”

2000, 2004 Listed in “Detroit’s Top Docs” for Alzheimer’s Disease, Metropolitan Detroit Monthly Hour Magazine

1996 – 1997 Listed in “The Best Doctors in America: Midwest Region”

1995 Doctor of Science (Honorary), MacMurray College

1985 - 1990 Clinical Investigator Development Award, NIH

1983 Young Alumnus of the Year, MacMurray College

1977 Alpha Omega Alpha

1977 Upjohn Achievement Award

ADMINISTRATIVE EXPERIENCE

Administrative Duties

2006 - present Medical Director, Cognitive Disorders Clinic, Center for Alzheimer’s Care, Imaging and Research, Department of Neurology, University of Utah

2005 - present Director, Center for Alzheimer’s Care, Imaging and Research, Department of Neurology, University of Utah

1994 – 2004 Associate Director, Michigan Alzheimer’s Disease Research Center

1989 – 2005 Director, Clinical Core, Michigan Alzheimer’s Disease Research Center

1984 – 2005 Director, Cognitive Disorders Clinic, Department of Neurology

Professional & Scientific Committees

International:

Sep 2006 -- Member, Geriatric Research Education and Clinical Center (GRECC) Advisory Committee, Department of Veterans Affairs Medical Center (Salt Lake City, UT)

2004 Scientific Committee Member, 2004 Alzheimer’s Imaging Consortium, pre- conference to the International Conference on Alzheimer’s Disease, Philadelphia, PA

National:

2004, 2006 Panel of Judges, Alzheimer’s Disease Neuroimaging Award, Alzheimer’s Association

2005 – present Scientific Advisory Board, Myriad Pharmaceuticals (Salt Lake City, UT).

2005 – present External Advisory Committee, Alzheimer’s Disease Research Center, University of Alabama (Birmingham, AL).

2003 – present Executive Committee Member, Geriatric Neurology Section, American Academy of Neurology

2002 – 2005 Executive Committee Member (elected position), Clinical Core Directors of Alzheimer Disease Centers, NIA

2002 – 2003 Clinical Task Force Member, Alzheimer Disease Centers, NIA

2002 PET Advisory Panel Member, NIH/NIA Neuroimaging Initiative

2001 – 2003 Neuroimaging Workgroup Member, The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging

1999 – 2003 Practice Committee Member, Geriatric Neurology Section, American Academy of Neurology

1999 – present Clinical Practice Committee Member, Geriatric Neurology Section, American Academy of Neurology

1997 Member of Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease”, The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association & National Institute on Aging

1997 Dementia Advisory Committee Member, Asset and Health Dynamics Study

1996 – 1997 Datasharing Committee Member, Alzheimer Disease Centers, NIA

Dec 9, 1991 Research Panel, Virginia M. Cullen Memorial Alzheimer’s Education Seminar, St. Joseph Mercy Hospital (Pontiac, MI).

Feb 4, 1991 Dementia Consensus Panel Member, Brain Imaging Council, Society of Nuclear Medicine (Tampa, FL).

1986 – 1987 President, American Society of Neurological Investigation

1985 – 1986 Secretary/Treasurer, American Society of Neurological Investigation

Regional:

1997 – 1998 Assisted Living Task Force Member, Michigan Department of Consumer and Industry Services.

1997 – 1998 Screening Advisory Committee Member, Michigan Medicaid Long-term Managed Care Plan (MI-Choice), Michigan Department of Community Health.

1996 – 1997 Mental Health and Aging Advisory Committee, Michigan Department of Community Health.

1994 – 1999 Dementia Services Coordinating Committee Member, Michigan Public Health Institute.

1987 – 1994 Member of Subcommittee on the Dementias, Chronic Disease Advisory Committee, Michigan Department of Public Health.

1987 Support Group Leaders, “Recent Research in Alzheimer’s Disease,” Alzheimer’s Disease and Related Disorders Association, Greater Ann Arbor Chapter (Ann Arbor, MI).

1986 – 2005 Physician Advisor, The Greater Washtenaw Area Tel-Med (Ann Arbor, MI).

1985 – 1992 Scientific Advisory Board Member, Alzheimer’s Disease and Related Disorders Association, Greater Ann Arbor Chapter (Ann Arbor, MI).

1985 Site Visit Team, Aging Review Committee, National Institute on Aging.

Grant Review Committees, Study Sections

2004 Director’s Review Committee Member, Life Sciences Division, Ernest Orlando Lawrence Berkeley National Laboratory.

Feb 21, 2003 Special Emphasis Panel Member, ZRG1-BDCN-1 (02), Brain Disorders and Clinical Neuroscience Initial Review Group, National Institutes of Health.

2003 Grant Reviewer, General Clinical Research Center, University of Michigan.

2000 – 2003 Abstract Reviewer, American Academy of Neurology Annual Meeting.

Jun 10, 2002 Ad Hoc Reviewer, BDCN-1, Brain Disorders and Clinical Neuroscience-1 Study Section, National Institutes of Health.

Oct 23-24, 2001 Special Emphasis Panel Member, Review of Mentored Clinical Scientist Development Awards in Alzheimer’s Disease and Related Dementias, NIA.

1997 – 2001 Initial Review Board Member, Medical and Scientific Advisory Council, Ronald and Nancy Reagan Research Institute, Alzheimer's Association.

1999 – 2000 Special Emphasis Panel Member, Review of Grants for Alzheimer’s Disease Pilot Clinical Trials, NIA.

1999 Reviewer, Alzheimer’s Disease Research Centers of California.

1989 Ad Hoc Reviewer, National Institute of Mental Health.

1989 Special Review Group Member, Human Development and Aging Study Section, National Institutes of Health.

1988 External Reviewer, Veterans Administration Merit Grants.

1987, 1989 Field Reader, Orphan Products Development Grants Program, FDA.

1986 Ad Hoc Reviewer, National Institute on Aging.

1985 - present Michigan Peer Review Organization.

1985, 1988 Ad Hoc Review Committee Member, Alzheimer’s Disease Research Centers, National Institute on Aging.

1985, 1986, 1987 Special Reviewer, Sensory Disorders and Language Study Section, National Institutes of Health.

1986 – present Member, Research Group on the Dementias, World Federation of Neurology

1983 Consultant Member, Orphan Products Development Initial Review Group, FDA.

Meeting Chair or Coordinator

International:

Sep 7, 2006 Co-Chair, Behavior in FTLD, 5th International Conference on Frontotemporal Dementia (FTD) (San Francisco, CA)

Jul 15, 2006 Co-Chair, Molecular Imaging Oral Session, Alzheimer’s Imaging Consortium, 10th International Conference on Alzheimer’s Disease (Madrid, Spain)

Regional:

Jun 17-18, 2006 Chair, Pilot Collaborative PET Imaging Trial, 3rd Expert Consensus Panel Meeting (Park City, UT)

Jan 21-22, 2006 Chair, Pilot Collaborative PET Imaging Trial, 2nd Expert Consensus Panel Meeting (SLC, UT)

April 1, 2003 Co-Chair, Session 18: “Aging and Dementia: Neuroimaging”, 55th Annual Meeting, American Academy of Neurology (Honolulu, HI)

2000 – 2001 Organizer, Monthly Clinical Conference, Michigan Alzheimer’s Disease Research Center (Ann Arbor, MI)

1999 Organizer and Moderator, “Workshop on Dementia Training for Primary Care Physicians”

1999 Organizer and Moderator, “Neuropsychological Assessment of Dementia”, Michigan Union

Oct 4-6, 1996 Organizer, “Conference on Chromosome 17-related Dementia” (Ann Arbor, MI)

May 1992 Co-Chair, Session 58: “Aging and Dementia VI: Functional Neuroimaging”, 44th Annual Meeting, American Academy of Neurology (San Diego, CA)

Apr 25, 1991 Co-Chair, “Aging and Dementia: Metabolism and Brain Imaging”, 43rd Annual Meeting, American Academy of Neurology (Boston, MA)

May 2, 1990 Co-Chair, “Aging and Dementia: Brain Imaging and Epidemiology”, 42nd Annual Meeting of the American Academy of Neurology (Miami Beach, FL)

1986 Organizing Committee Member, 1st Meeting of Scientific Investigators in Michigan Study Alzheimer’s Disease and Related Disorders (Dearborn, MI)

Oct 8, 1986 Organizer and Moderator, “The Future of Academic Neurology”, 6th Annual Meeting of the American Society for Neurological Investigators (Boston, MA)

Apr 9, 1986 Organizing Committee, 1st Meeting of Scientific Investigators in Michigan Study Alzheimer’s Disease and Related Disorders (Dearborn, MI).

PROFESSIONAL ACTIVITIES

Membership in Professional SocietiesAmerican Academy of Neurology, 1980--

Junior Member, 1980-1983Active Member, 1983-1987Fellow, 1987--Member, Geriatric Neurology Section, 1996--

Clinical Practice Committee, 1999--American Association for the Advancement of Science, 1985--

Section on NeurosciencesSection on Medical SciencesSection on Societal Impacts of Science and Engineering

American Neurological Association, 1992--American Society for Neurological Investigation, 1981-1991

Secretary-Treasurer, 1985-1986President, 1986-1987

International Neuropsychology Society, 1985--International Society of Cerebral Blood Flow and Metabolism, 1988--Michigan Neurological Association, 1984--World Federation of Neurology Research Group on the Dementias, 1986--

SCIENTIFIC and PROFESSIONAL MEETINGS ATTENDED (without presentations)

Dec 14, 2006 External Advisory Committee Meeting, University of Alabama (Birmingham, AL)

Dec 6, 2006 Personalized Medicine in Utah Conference & Reception (SLC, UT)

Oct 8-9, 2006 Alzheimer’s Disease Neuroimaging Initiative (ADNI) Fall Steering Committee Meeting (Chicago, IL)

Sep 6-8, 2006 5th International Frontotemporal Dementia Conference (San Francisco, CA)

Aug 9, 2006 Cache County Memory Study (CCMS) Research Retreat (Logan, UT)

Jun 16-18, 2006 Pilot Collaborative PET Imaging Trial Expert Consensus Panel Meeting (Park City, UT)

Apr 4, 2006 The American Academy of Neurology 58th Annual Meeting (San Diego, CA)

Apr 3, 2006 Alzheimer’s Disease Neuroimaging Initiative (ADNI) Spring Steering Committee Meeting (San Diego, CA)

Jan 21-22, 2006 Pilot Collaborative PET Imaging Trial Expert Consensus Panel Meeting (SLC, UT)

Oct 24-25, 2005 University of Alabama Alzheimer’s Disease Research Center, External Advisory Committee Meeting (Birmingham, AL)

Jul 17-22, 2004 The 9th International Conference on Alzheimer’s Disease and Related Disorders (Philadelphia, PA)

COMMUNITY ACTIVITIES

Community Leadership2005 – now Member, Utah State Commission on Aging (Salt Lake City, UT)

1986 – 2005 Physician Advisor, The Greater Washtenaw Area Tel-Med (Ann Arbor, MI)

1985 – 1992 Advisory Board, ADRDA, Greater Ann Arbor Chapter (Ann Arbor, MI)

PUBLICITY and PRESS

International:

Mar 8, 2005 Interview (television): “Sporadic CJD”, The National, Canadian Broadcasting Corporation. Anita Mielewczyk, producer; Kelly Crowe, reporter; Randy Shedlowich, cameraman.

Jan 20, 2005 Interview (telephone): “Sporadic CJD”, The National, Canadian Broadcasting Corporation, Prab Dhanoa.

May 2, 2002 Interview: “Two Cases of Early Onset Sporadic Creutzfeldt-Jakob Disease in Michigan”, New Scientist (London, England), Deborah McKenzie

National:

Nov 5, 2004 Interview (telephone): “The Alzheimer’s Disease Neuroimaging Initiative and the Future of Imaging in Dementia”, Advance for Radiology, Joyce Ward.

Oct 14, 2004 Interview (telephone): “The Role of PET in the Early Diagnosis of Alzheimer’s Disease”, Diagnostic Imaging, Chris Kaiser.

Jan 14, 2004 Interview: “Advanced Planning for Dementia Care”, ADVANCE for Occupational Therapy Practitioners, a publication of Merion Advance newsmagazines, Jill Glomstad.

Mar 25, 2003 Interview (telephone): “Comment on ‘Creutzfeldt-Jakob Disease in Deer and Elk Hunters’ by Murinova et al., Neurology 2003; 60:A190”, New Scientist, Anil Ananthaswamy.

Oct 22, 2002 Interview (telephone): “PET Imaging in Alzheimer’s Disease”, Associated Press, Daniel Haney.

Aug 27, 2002 Interview: “Two Cases of Prion Disease in Michigan”, The Todd Mundt Show, National Public Radio and WUOM, Todd Mundt. Broadcast and webcast 9/6-20/2002.

Sep 2002 Interview: “Hypotension May Cause Frontotemporal Dementia”, Neurology Today, Kurt Samson. Published with portrait, pg. 35-6.

May 15, 2002 Interview: “Two Cases of Early Onset Sporadic Creutzfeldt-Jakob Disease in Michigan”, Associated Press (Detroit, MI), Andrea Menzie.

May 1, 2002 Interview: “Two Cases of Early Onset Sporadic Creutzfeldt-Jakob Disease in Michigan”, Wall Street Journal, Antonio Regalado.

Apr 26, 2002 Interview: “Two Cases of Early Onset Sporadic Creutzfeldt-Jakob Disease in Michigan”, USA Today, Anita Manning. Appeared 4/29/2002.

Apr 6, 2001 Interview: “Laboratory Testing in Alzheimer’s Disease”, Laboratory Advances, Pam Tarapchak. Excerpts published in “Shining Light into the Dark”, Advance for Administrators of the Laboratory 2001: 10 (7, Jul) 70-76.

Jan 12, 2001 Interview: “Strategies for Preventing Alzheimer’s Disease”, CBS Healthwatch, Peter Downs.

Regional:

Nov 27, 2006 Live TV Appearance: Good Things Utah, Channel 4 ABC (Salt Lake City, UT)

Nov 22, 2006 Interview: Lois Collins, Deseret News (Salt Lake City, UT)

Nov 22, 2006 Live Radio Appearance: KCPW Mid-Day Metro (Salt Lake City, UT)

Nov 10, 2006 Interview: Julie Roberts, ReDirect Marketing for the Brain Institute at the University of Utah (Salt Lake City, UT)

Aug 29, 2006 Podcast Recording, Interviewer: Phil Sahm, University of Utah Public Relations

Apr 2006 Featured: “Incidence of Alzheimer’s Disease on the Rise in Utah”, Utah Health Magazine.

Nov 28, 2005 Interview: “Healing Memory: U Alzheimer’s Center to fill need for research and treatment”, Daily Utah Chronicle, The University of Utah, Morgan Ratcliffe.

Nov 21, 2005 Featured: “An Alzheimer’s Program for the 21st Century: Top Expert to Open Clinic at U of U, Join New Brain Institute”, University of Utah News and Public Relations Press Release, Phil Sahm.

Nov 2005 Author, op-editorial: “New Hope for Alzheimer’s Disease”, The Salt Lake Tribune. Co-author: Michael Wood, President of the Board of Directors for the Utah Chapter of the Alzheimer’s Association.

Nov 2005 Interview: KUER, KUEN

Oct 28, 2004 Interview: “The Alzheimer’s Disease Neuroimaging Initiative”, Michigan Daily (Ann Arbor, MI), Genevieve Lampinen. Published Nov 2, 2004.

Oct 15, 2004 Interview: “The Alzheimer’s Disease Neuroimaging Initiative”, WKZO AM 590 radio (Kalamazoo, MI), Jim O’Connell.

Oct 13, 2004 Interview (taped): “The Alzheimer’s Disease Neuroimaging Initiative”, WUOM radio (Ann Arbor, MI), Tracy Similton.

Oct 13, 2004 Interview (taped): “The Alzheimer’s Disease Neuroimaging Initiative”, WAAM radio (Ann Arbor, MI), Glen Law.

Jun 29, 2004 Interview (telephone): “FDG-PET and Biomarkers in the Early Diagnosis of Alzheimer’s Disease”, Boston Globe, Alice Dembner. Appeared in the Tuesday Science Section, July 6, 2004.

Feb 13, 2004 Interview: “Creutzfeldt-Jakob Disease in Michigan”, WXYZ TV, Channel 7, JoAnn Purtan.

May 13, 2003 Interview: “African American Health Care in Detroit – the Legacy of Segregation”, WDET-FM (Detroit, MI), Craig Fahle. For a series to be aired in June 2003.

Oct 4, 2002 Interview (videotaped): “PET Imaging in Alzheimer’s Disease”, Victor/Harder Productions of West Bloomfield Michigan, Fran Victor.

Aug 14, 2002 Interview: “Likely Higher than Expected Occurrence of Prion Disease in Young People”, Connecticut Post (Bridgeport, CN), Marion Brown.

Apr 30, 2002 Interview: “Two Cases of Early Onset Sporadic Creutzfeldt-Jakob Disease in Michigan”, Fox 2 Detroit, Bob Gallagher. Aired 4/30/02.

Apr 26, 2002 Interview: “Two Cases of Early Onset Sporadic Creutzfeldt-Jakob Disease in Michigan”, The Rocky Mountain News (Denver, CO), Lou Kilzer. Aired 4/27/02.

Oct 4, 2001 Interview: “Healthy Aging and Brain Function”, Michigan Talk Radio, Bob White.

Sep 27, 2001 Interview: “Creutzfeldt-Jakob Disease in a Young Man from Port Huron”, Port Huron Times-Herald, Amber Hunt.

Feb 21, 2001 Interview: “Update on Alzheimer’s Disease Research”, Traverse City, MI.

Nov 10, 2000 Interview (one-hour radio interview and listener call-in): “Documenting the History of African-American Health Care in Southeast Michigan”, WAAM, the Ted Heusel Show (Ann Arbor, MI), John Bacon.

Dec 7, 1999 Interview (videotaped): “Clinical Trial to Prevent Alzheimer’s Disease”, Ivanhoe Productions (Orlando, FL), Mary Zagar White.

Nov 10, 1999 Interview (videotaped): “Clinical Trial to Prevent Alzheimer’s Disease”, MedStar TV Health News (Allentown, PA), Karen Zeitlin.

Sep 1999 Interview (videotaped): “Clinical Trial to Prevent Alzheimer’s Disease”, Victor/Harder Productions (West Bloomfiel, MI), Fran Victor.

Jun 10, 1997 Interview: “Alzheimer's Research and the Cancer-Geriatric Center at the University of Michigan”, Oakland Press, Julie Balunkel.

Jun 3, 1997 Interview: “Vitamin E and Alzheimer's Disease”, Warren Pierce Radio network and WAAM, Warren Pierce.

Apr 25, 1997 Interview (on-air): “Vitamin E and Alzheimer's Disease”, WAAM (Ann Arbor, MI), Dave Pekrul.

Apr 24, 1997 Interview (on-air): “Vitamin E and Alzheimer's Disease”, WWJ (Detroit, MI).

Apr 23, 1997 Interview: “Vitamin E and Alzheimer's Disease”, The Detroit News, Pat Amstett. Front-page story appeared Apr 24, 1997.

Apr 23, 1997 Interview: “Vitamin E and Alzheimer's Disease”, WAAM (Ann Arbor, MI).

Apr 23, 1997 Interview: “Vitamin E and Alzheimer's Disease”, WUOM (Ann Arbor, MI), Joan Silvie.

Apr 15, 1997 Interview: “Familial Alzheimer's Disease”, WDIV Channel 4 Detroit, Delle Warner.

Oct 28, 1996 Interview: “New Brain Illness Mimics Alzheimer's”, The Detroit News, James Tobin.

Oct 1996 Interview: “Health Update” (Chromosme 17 related Dementia Conference), WWJ.

Oct 1, 1996 Interview on Chromosome 17-related Dementia, Channel 7 WXYZ Detroit, Jerry Hodak.

Nov 8, 1994 Interview (on-air with audience call-in): “Ronald Reagan and Alzheimer’s Disease”, WXYT Detroit, David Newman.

Oct 3, 1994 Interview (television): “Alzheimer’s Disease”, Channel 4 WDIV Detroit, Delle Warner.

Aug 29, 1994 Interview (radio): “Alzheimer’s Disease Today”, WMPL (Houghton, MI), Mike Foster.

Oct 19, 1993 Interview (radio): “Community Outreach Education Project: A Thumb Area Response”, WLEW (Bad Axe, MI), Craig Routzahm.

Oct 19, 1993 Interview (radio): “Community Outreach Education Project: A Thumb Area Response”, WMIC (Sandusky, MI), Bob Armstrong.

Mar 20, 1991 Interview: “THA, Alzheimer’s Disease and the FDA”, John Del-Monice Show, WAAM.

Oct 29, 1987 Interview: “Alzheimer’s Disease Awareness Month”, Fred Hindley Show, WUOM.

Nov 9, 1987 Interview: “Alzheimer’s Disease”, Ted Heusel Show, WAAM.

Nov 19, 1986 Interview (radio): “Alzheimer’s Disease and THA”, J. P. McCarthy Show, WJR Detroit.

Nov 13, 1986 Interview (on-air with audience call-in): “Alzheimer’s Disease Awareness Month”, Ted Heusel Show, WAAM (Ann Arbor, MI).

Aug 8, 1985 Interview: “PET Scanning in Alzheimer’s Disease Research”, Channel 7 WXYZ Detroit, Jerry Hodak.

UNIVERSITY COMMUNITY ACTIVITIES

Leadership

University of Utah:

Mar 2006 – Member, Steering Committee for Research Strategic Planning, School of Medicine

Dec 2005 – Member, Steering Committee, Center on Aging

Sep 2005 – Member, Psychiatry Chair Search Committee, School of Medicine

University of Michigan:

2003 Faculty Search Committee, Division of Neuropsychology, Department of Psychiatry

2002 Interim Chair, Appointments, Promotions, and Awards Committee, Department of Neurology

2000 – Member, Faculty Network for the Cultural Competency Curriculum

2000 – Member, Appointments, Promotions, and Awards Committee, Department of Neurology

2000 – 2001 Executive Committee, Institute of Gerontology

1998 – Mentor Panel, Research Development Core of the University of Michigan Claude Pepper Older Americans Independence Center

1996 – Multidisciplinary Advisory Group, Postdoctoral Training Program in Professional Psychology

1994 – Data and Safety Monitoring Board, General Clinical Research Center

1994 – 1999 Executive Committee, Integrated Geriatric Fellowship Program

1994 – 1995 Department Coordinator, Advances in Internal Medicine Course

1992 – Project Reviewer, General Clinical Research Center

1991 – Geriatric Center Clinical Coordinating Committee

1991 – 1997 Geriatric Center Facilities Planning Committee

1991 – 1995 Faculty Recruitment Committee, Department of Neurology

1990 – Executive Committee, Michigan Alzheimer’s Disease Research Center

1986 – 1987 Chairman, Database Management Committee, Positron Emission Tomography Center

1984 – 1990 Utilization Review, Physician Advisor

Courses Taught

University of Michigan:

2001 Hartford Integrative Geriatric Seminar, School of Social Work

2000 Societal Analysis of Aging (HMP 673), School of Public Health1997, 1998 Independent Study in Neurology, Neurobiology of Alzheimer's Disease and Related

Dementias1997-2002 Introduction to the Patient, Clinical Skills Laboratory, Component I1993-2004 Neuroscience Sequence, Component II1984-2005 Neurology 731, Junior Clerkship1984-2005 Neurology 841, Elective Senior Clerkship1984-2005 Presentations at Neurology Grand Rounds1985, 89, 95, 97 Senior Clinical Pharmacology and Therapeutics (PHMRX-D.101.V) 1992-1995 Professor’s Rounds, Ann Arbor Veterans Administration Hospital1985-1993 Neural and Behavioral Science 6001985, 1988 Neuroscience 7311985 Dental Neurosciences 5031984 Medical Student Career Counselor1984 Preceptor, Introduction to Clinical Sciences 6001984 Senior Year Counselor

University of Michigan Postgraduate Program:

Nov 3, 2001 “Recognition, Initial Assessment and Diagnosis of Alzheimer’s Disease”, Pathways to More Effective Treatments of Dementia, Livonia Marriott, Livonia, MI

Nov 12, 1998 “Update on Alzheimer’s Disease and Other Dementias”, Advances in Neurology and Geriatric Psychiatry

Sep 4, 1997 "Disorders that Mimic Alzheimer's Disease", Neurological and Behavioral Disorders in the Elderly

Mar 12, 1997 "Dementia Update", Family Practice 1997: 21st Annual Spring Review CourseSep 6, 1996 "Panel Discussion on the Care of the Cognitively Impaired Patient: Autonomy, Substituted

Judgement, Research and Teaching”, Critical Clinical Issues in the Care of Older Adults: Ethics and Managed Care

Apr 25, 1995 “Dementia Care in the Age of Health Reform and Malpractice”, 23rd Annual Spring Update on Advances in Internal Medicine,

Mar 15, 1994 Family Practice 1994: 18th Annual Spring Review Course, “New Practical Considerations in Treating Dementia”

Apr 30, 1993 “Current Approaches to the Evaluation of Dementia”, 21st Annual Spring Update on Advances in Internal Medicine,

Mar 19, 1993 “Alzheimer Disease”, Family Practice 1993: 17th Annual Spring Review Course, Dec 11, 1992 General Medicine for Psychiatrists- ”Deliriium and Dementia”, “Behavioral Manifestations of

Neurological Disease”Sep 10, 1992 Critical Clinical Issues in the Care of the Elderly: Drugs and Their Implications, “Alzheimer’s

Disease”Series: Kellogg Interdisciplinary Team Training in Geriatrics, Ann Arbor, Michigan, “Dementia”

Apr 24, 1990 “Dementia - Diagnostic Evaluation”May 22, 1990 “Dementia - Diagnostic Evaluation” Oct 2, 1990 ”Management of Dementia”Nov 6, 1990 ”Management of Dementia”

Oct 19, 1987 Critical Clinical Issues in the Care of the Elderly: Illness Prevention and Early Detection, “Assessing Competence: Can the Patient Decide?”

May 13, 1987 15th Annual Spring Update, Advances in Internal Medicine, “The Application of PET Scanner Techniques and Understanding Dementia”

Mar 1985 Family Practice - “Evaluation of Alzheimer’s Disease”

Students Supervised

Graduate Students:

Winter term 2004 Kelly O’Brien, MS student, Dept of Biostatistics. Supported from research incentive account for PET data analysis. Supervised by Thomas Nichol, Ph.D.

Predoctoral:

1990, 91, 95 Gamil Mahmoud Tourky, MD, MSc (Dr. P.H., epidemiology)October 1990 preliminary examination, December 1991 pre-candidacy examination (proposal defense), July 1995 successful thesis defense. Thesis: “Risk factors for Alzheimer's disease: an autopsy-based case-control study” (support: Egyptian government grant). Subsequent positions: Professor, University of Tanta, Egypt

1994 Sony Kilgore, University of Michigan 2nd year medical student, AFAR-John A. Hartford Foundation Medical Student Training Program in Geriatrics FellowshipPrimary Research Project: An Assessment of Apolipoprotein E Frequency and Age-Related Risks of Alzheimer’s Disease (Support: AFAR-John A. Hartford Foundation Medical Student Training Program in Geriatrics Fellowship). Degree: M.D. (1996): University of Michigan. Subsequent positions: pathology resident, Cleveland Clinic Foundation

1991 Savitha Krishnan, University of Michigan 2nd year Inteflex studentPrimary Research Project: Predictors of Response to Treatment in Patients with Alzheimer’s Disease (support: AFAR-John A. Hartford Foundation Medical Student Training Program in Geriatrics Fellowship). Subsequent positions: obstetrics and gynecology resident, George Washington University Hospitals

1990 John W. Chen, University of Michigan 2nd-year medical studentPrimary Research Project: The Relationship of Mini-mental State Examination (MMSE) and Cerebral Glucose Metabolism in Alzheimer’s Disease (support: AFAR-John A. Hartford Foundation Medical Student Training Program in Geriatrics Fellowship). Subsequent positions: Neurology resident, UCLA

1989 John W. Chen, University of Michigan 1st-year medical studentPrimary Research Project: A Comparison of SPECT and PET Functional Brain Imaging in Dementia (support: AFAR-John A. Hartford Foundation Medical Student Training Program in Geriatrics Fellowship)

1988 Holly Brenner (Gross), University of Michigan 2nd-year medical studentPrimary Research Project: A Comparison of Blood Flow and Glucose Metabolic Rate in the Brains of Patients with Progressive Supranuclear Palsy Using Positron Emission Tomography (support: University of Michigan School of Medicine Biomedical Research Council). Subsequent positions: ophthalmology resident, University of Michigan Hospitals

1988 Mary S. Hansen (Grant), University of Michigan 2nd-year medical studentPrimary Research Project: The Effects of Pramiracetam and THA on Local Rates of Cerebral Glucose Metabolism as Measured with 18-Fluoro-deoxy-D-glucose Positron Emission Tomography in Patients with Alzheimer’s Disease (support: University of Michigan School of Medicine Biomedical Research Council). Subsequent positions: psychiatry resident, University of Michigan Hospitals

1987 Mary S. Hansen (Grant), University of Michigan 1st-year medical studentPrimary Research Project: Lateral and Mesial Temporal Glucose Metabolism in Alzheimer’s Disease (support: University of Michigan School of Medicine Biomedical Research Council)

1985 Jeff Wilt, University of Michigan 2nd-year medical studentPrimary Research Project: A Comparison of Arterial versus Arteriovenous Sampling in the Measurement of Glucose Metabolism by Positron Emission Tomography (support: University of Michigan School of Medicine Biomedical Research Council). Subsequent positions: orthopedic surgery resident

Geriatric Medicine Fellow Research:

Oct 99 – Oct 00 Delia Ochoa, D.O. Degree: DO (1996): Michigan State University; Fellowship: University of Michigan. Primary Research Project: Identifying Dementia in Depressed Elderly Patients (support: V.A. Geriatric Medicine Fellowship). Subsequent positions: Physician, Holy Cross Medical Group (Pompano, FL).

Postdoctoral:

2005 – current David R. Shprecher, D.O.Degree: DO (2003): Lake Erie College of Osteopathic Medicine; Residency: University of Utah. Primary Research Project: Pilot PET Collaborative Imaging Trial. Subsequent Positions: Neurology resident, University of Utah (Salt Lake City, UT).

2004 - current Paul Motika, M.D.Degree: MD (2003): University of Rochester; Residency: University of Michigan. Primary Research Project: A case of Creutzfeldt-Jakob disease presenting clinically and radiographically as AD (support: unknown). Subsequent Positions: Neurology Resident, University of Rochester School of Medicine & Dentistry, NY.

Apr 01 – Mar 06 Kenneth Langa, M.D.Degree: MD (1994): University of Chicago; Residency: Internal Medicine, University of Michigan. Primary Research Project: Identifying Cases and Costs of Dementia in the U.S. (support: NIA K08 award, K08-AG19180). Subsequent positions: Lecturer and Assistant

Professor of Internal Medicine, Faculty Associate, Institute for Social Research, University of Michigan (Ann Arbor, MI).

2002 - 2003 Pam Alvarez, M.D.Degree: MD (1998): Chicago Medical School; Residency: University of Michigan. Primary Research Project: Clinical and pathological features of early-onset familial AD caused by a novel (Leu241HIS) presenilin-1 mutation (support: unknown). Subsequent Positions: Private Practice (Tacoma, WA).

2001 - 2003 David Cohen, M.D.Degree: MD (2000): New Jersey Medical School; Internship, Residency, Fellowship: University of Michigan. Primary Research Project: Sporadic Creutzfeldt-Jokob disease presenting with nonconvulsive status epilepticus (support: unknown). Subsequent Positions: Neurologist, Robert Wood Johnson University Hospital (New Brunswick, NJ).

2001 - 2002 Amanda Peltier, M.D.Degree: MD (1998): Ohio State College of Medicine; Residency (2002): Neurology, University of Michigan. Primary Research Project: Two concurrent cases of early-onset sporadic Creutzfeldt-Jakob disease in Michigan (support: unknown). Subsequent Positions: Assistant Professor of Neurology, Vanderbilt University (Nashville, TN).

2001 - 2002 Patience Reading, M.D.Degree: MD (unknown): University of Texas Southwestern; Residency/Fellowship: Internal Medicine, University of Michigan. Primary Research Project: Two concurrent cases of early-onset sporadic Creutzfeldt-Jokob disease in Michigan (support: unknown). Subsequent Positions: Neurologist, Austin Diagnostic Clinic (Austin, TX).

2001 - 2002 Ming Hong, M.D.Degree: MD (unknown): Peking Union Medical College; Residency: University of Michigan. Primary Research Project: Spontaneous intracranial hypotension causing reversible frontotemporal dementia (support: unknown). Subsequent Positions: Private Practice (Washington, DC).

Mar 00 – Mar 01 Eui-Ju Son, M.D., Assistant Professor of Neurology, University of MichiganDegree: MD (1988) and Residency: Chonnam University (South Korea). Primary Research Project: Extrapyramidal Signs in Dementia with Lewy Bodies and Alzheimer’s Disease (support: Korean Funds). Subsequent positions: Assistant Professor of Neurology, Seonam University (Kwangju, South Korea).

Jul 99 – 01 Sinfree Makoni Ph.D., Associate Professor of Linguistics, University of Cape Town (South Africa), DuBois-Mandela-Rodney Postdoctoral Fellow, Center for Afro-American and African StudiesDegree: PhD, Linguistics (1989): University of Edinburgh, Scotland. Primary Research Project: Language and Dementia Among African Americans (support: University of Michigan funds), Pilot Grant: Michigan Center for Urban African American Aging Research (support: NIH Grant P30-AG15281). Subsequent positions: Associate Professor Communication Sciences and Disorders, Long Island University (Brooklyn, NY); Professor, Center For Aging, University of Cape Town (South Africa).

1999 – 2001 Paolo Moretti, M.D.Degree: MD (1990): University of Padua, Italy; Residency: University of Michigan. Primary Research Project: Early-onset familial Alzheimer’s disease and spastic paraparesis associated with a novel insertional mutation of the presenilin 1 gene (support: unknown). Subsequent Positions: Assistant Professor of Neurology and Molecular and Human Genetics, Baylor College of Medicine (Houston, TX).

Jul 97 – Jun 01 Andrea Bozoki, M.D. Degree: MD (1993): SUNY Downstate; Residency: Neurology, University of Michigan. Primary Research Project: Functional MRI of Memory Encoding versus Retrieval in Normal Elderly and Alzheimer Disease (support: HRSA grant D31-AH90005 (2 years); NIH Grant T32-AG00114). Subsequent positions: Assistant Professor, Michigan State University (Lansing, MI).

Jul 95 – Jun 97 Judith Heidebrink, M.D.(1994): University of Texas Southwestern; Residency: Neurology, University of Michigan. Primary Research Project: Neuropharmacological Challenges in Dementia (support: HRSA grant D31-AH90005; NIH grant T32-NS07222). Subsequent/current positions: Lecturer and Assistant Professor, Department of Neurology, University of Michigan (Ann Arbor, MI).

Jul 93 – Jun 95 Daniel Murman, M.D. Degree: M.D. (1989): University of Nebraska; Residency: Neurology, University of Michigan. Primary Research Project: The Effect of Apolipoprotein E on Clinical Features of Dementia

(support: NIH Grant T32-NS07222; HRSA grant D31-AH90005; NIH grant T32-AG00114). Subsequent positions: Lecturer of Neurology, Assistant Professor of Physical Medicine and Rehabilitation (College of Osteopathic Medicine) and Department of Medicine (College of Human Medicine, Center for Clinical Neuroscience and Ophthalmology), Michigan State University. Current positions: Director, Geriatric Neurology and Memory Disorders Clinic, Clinical Center, Michigan State University, Lansing MI; Coordinator, Michigan Dementia Postmortem Network, Michigan State University (Lansing, MI).

BIBLIOGRAPHYNorman L. Foster, M.D.

ORIGINAL PUBLICATIONS

1. Foster NL and Campbell B. The effect of diphenylhydantoin on the microbial assay of serum folate, Clinical Biochemistry, 1976, 9, 22-23.

2. Foster NL. Progressive supranuclear palsy and hyperkalemic periodic paralysis. Archives of Neurology, 1980, 37, 461-446.

3. Foster NL, Wing SD, and Bray PF. Metrizamide ventriculography in the diagnosis of syringomyelia. Neurology, 1980, 30, 1323-1326.

4. Chase TN, Brooks RA, DeLaPaz RL, DiChiro G, Durso R, Fedio P, Foster NL, Kessler RM, Kornblith PL, Kufta CV, Manning RG, Newmark ME, Patronas NJ, Porter R, Sato S, Smith BH, and Theodore WH. Positron emission tomographic studies of epilepsy, brain tumors, and Alzheimer’s disease. Psychopharmacology Bulletin, 1982, 18(3):3-6.

5. Foster NL, Chase TN, Denaro A, Hare TA, and Tamminga CA. THIP treatment of Huntington’s disease. Neurology, 1983, 33, 637-639.

6. Foster NL, Chase TN, Fedio P, Patronas NJ, Brooks RA, and DiChiro G. Alzheimer’s disease: focal cortical changes shown by positron emission tomography. Neurology, 1983, 33, 961-965.

7. LeWitt PA, Ward CD, Larsen TA, Raphaelson MI, Newman RP, Foster NL, Dambrosia J, and Calne DB. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology, 1983, 33, 1009-1014.

8. Chase TN, Foster NL, Fedio P, Brooks R, Mansi L, and DiChiro G. Regional cortical dysfunction in Alzheimer’s disease as determined by positron emission tomography. Annals of Neurology, 1984, 15, S170-S174.

9. Chase TN, Foster NL, Fedio P, Brooks R, Mansi L, Kessler R, and DiChiro G. Gilles de la Tourette syndrome: studies with fluorine-18-labeled fluorodeoxyglucose positron emission tomographic method. Annals of Neurology, 1984, 15, S175.

10. Karson CN, Burns RS, LeWitt PA, Foster NL, and Newman RP. Blink rates and disorders of movement. Neurology, 1984, 34, 677-678.

11. Foster NL, Newman RP, LeWitt PA, Gillespie MM, Larson TA, and Chase TN. Peripheral beta-adrenergic blockade treatment of parkinsonian tremor. Annals of Neurology, 1984, 16, 505-508.

12. Foster NL, Newman RP, LeWitt PA, Gillespie MM, and Chase TN. Treatment of resting tremor by beta-adrenergic blockade. American Heart Journal, 1984, 108, 1173-1177.

13. Chase TN, Fedio P, Foster NL, Brooks R, DiChiro G, and Mansi L. Cortical localization of WAIS subtest performance by fluorodeoxyglucose positron emission tomography. Archives of Neurology, 1984, 41, 1244-1247.

14. Foster NL, Chase TN, Mansi L, Brook R, Fedio P, Patronas NJ, and DiChiro G. Cortical abnormalities in Alzheimer’s disease. Annals of Neurology, 1984, 16, 649-654.

15. Grimes AM, Grady CL, Foster NL, Sunderland T, and Patronas NJ. Central auditory function in Alzheimer’s disease. Neurology, 1985, 35, 352-358.

16. Hurst JH, LeWitt PA, Burns RS, Foster NL, and Lovenberg W. CSF dopamine-B-hydroxylase activity in parkinsonian patients. Neurology, 1985, 35, 565-568.

17. Newman RP, LeWitt PA, Shults C, Bruno G, Foster NL, Chase TN, and Calne, DB. Dystonia: treatment with bromocriptine. Clinical Neuropharmacology, 1985, 8, 328-333.

18. Foster NL, Tamminga CA, O’Donohue TL, Taninioto K, Bird ED, and Chase TN. Brain choline acetyltransferase activity and neuropeptide Y concentrations in Alzheimer’s disease. Neuroscience Letters, 1986, 63, 71-75.

19. Irving CS, Marks L, Klein PD, Foster NL, Gadde PL, Chase TN, and Samuel D. New evidence for taurine biosynthesis in man obtained from 1802 inhalation studies. Life Sciences, 1986, 38, 491-495.

20. Foster NL, Chase TN, Patronas NJ, Gillespie MM, and Fedio P. Cerebral mapping of apraxia in Alzheimer’s disease by positron emission tomography. Annals of Neurology, 1986, 19, 139-143.

21. Tamminga CA, Gotts MD, Thaker GK, Alphs LD, and Foster NL. Dopamine agonist treatment of schizophrenia using N-propylnorapomorphine. Archives of General Psychiatry, 1986, 43, 398-402.

22. Mohr E, Burns G, Foster NL, Gillespie M, Cox C, Hare TA, Tamminga C, Fedio P, and Chase TN. GABA-agonist therapy of Alzheimer’s disease. Clinical Neuropharmacology, 1986, 9, 257-263.

23. Martin A, Brouwers P, Lalonde F, Cox C, Teleska P, Fedio P, Foster NL, and Chase TN. Towards a behavioral typology of Alzheimer’s patients. Journal of Clinical and Experimental Neuropsychology, 1986, 8, 594-610.

24. Tamminga CA, Foster NL, Fedio P, Bird ED, and Chase TN. Alzheimer’s disease: low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism. Neurology, 1987, 37, 161-165.

25. Foster NL, VanDerSpek AFL, Aldrich MS, Berent S, Hichwa RH, Sackellares JC, Gilman S, and Agranoff, BW. The effect of diazepam sedation on cerebral glucose metabolism in Alzheimer’s disease as measured using positron emission tomography. Journal of Cerebal Blood Flow and Metabolism, 1987, 7, 415-420.

26. Berginer VM, Foster NL, Sadowsky M, Townsend JA, and Siegel, GJ. Psychiatric disorders in cerebrotendinous xanthomatosis. American Journal of Psychology, 1988, 145, 354-357.

27. Sheridan PH, Sato S, Foster NL, Bruno G, Cox C, Fedio P, and Chase TN. Relation of EEG alpha background to parietal lobe function in Alzheimer’s disease as measured by positron emission tomography and psychometry. Neurology, 1988, 38, 747-750.

28. Foster NL, Mountz JM, Bluemlein LA, Ackermann RJ, Petry NA, and Kuhl, DE. Blood flow imaging of posterior circulation stroke. Use of technetium Tc 99m hexamethylpropleneamine oxime and single photon emission computed tomography. Archives of Neurology, 1988, 45, 687-690.

29. Foster NL, Gilman S, Berent S, Morin EM, Brown MB, and Koeppe, RA. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Annals of Neurology, 1988, 24, 399-406.

30. Mountz JM, Foster NL, Ackermann RJ, Bluemlein LA, Petry NA, and Kuhl, DE. SPECT imaging of Moyamoya disease using 99m-Tc-HM-PAO: comparison with computed tomography findings. Journal of Computed Tomography, 1988, 12, 247-250.

31. Foster NL, Aldrich MS, Bluemlein LA, White RF, and Berent, S. Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep. Neurology, 1989, 39, 257-261.

32. Grady CL, Grimes AM, Patronas N, Sunderland T, Foster NL, and Rapoport SI. Divided attention, as measured by dichotic speech performance, in dementia of the Alzheimer type. Archives of Neurology, 1989, 46, 317-320.

33. Aldrich MS, Foster NL, White RF, Bluemlein LA, and Prokopowicz G. Sleep abnormalities in progressive supranuclear palsy. Annals of Neurology, 1989, 25, 577-581.

34. Mountz JM, Modell JG, Foster NL, DuPree ES, Ackermann RJ, Petry NA, Bluemlein LE, and Kuhl, DE. Prognostication of recovery following stroke using the comparison of CT and technetium-99m HM-PAO SPECT. Journal of Nuclear Medicine, 1990, 31, 61-66.

35. Giordani B, Boivin MJ, Hall AL, Foster NL, Lehtinen SJ, Bluemlein LA, and Berent, S. The utility and generality of Mini-Mental State Examination scores in Alzheimer’s disease. Neurology, 1990, 40, 1894-1896.

36. Bromberg MB, Aldrich MS, Foster NL, and Berent, S. The Kluver-Bucy syndrome preceding ventricular enlargement in normal pressure hydrocephalus. Dementia, 1990, 1, 169-174.

37. Goldman R, Axelrod BN, Giordani B, Foster NL, and Berent, S. Longitudinal sensitivity of the Fuld cholinergic profile to Alzheimer’s disease. Journal of Clinical and Experimental Neuropsychology, 1992, 14, 566-574.

38. Boivin MJ, Giordani B, Berent S, Amato DA, Lehtinen S, Koeppe RA, Buchtel HA, Foster NL, and Kuhl, DE. Verbal fluency and positron emission tomographic mapping of regional cerebral glucose metabolism. Cortex, 1992, 28, 231-239.

39. Foster NL, Gilman S, Berent S, Sima AAF, D’Amato C, Koeppe RA, and Hicks, SP. Progressive subcortical gliosis and progressive supranuclear palsy can have similar clinical and PET abnormalities. Journal of Neurology, Neurosurgery, and Psychiatry, 1992, 55, 707-713.

40. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J, and the Tacrine Study Group. A controlled trial of tacrine in Alzheimer’s disease. Journal of the American Medical Association, 1992, 268, 2523-2529.

41. Kluin KJ, Foster NL, Berent S, and Gilman S. Perceptual analysis of speech disorders in progressive supranuclear palsy. Neurology, 1993, 43, 563-566.

42. Shope JT, Holmes SB, Sharpe PA, Goodman C, Izenson S, Gilman S, and Foster NL. Services for persons with dementia and their families: a survey of information and referral agencies in Michigan. Gerontologist, 1993, 33, 529-533.

43. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI, and Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. Journal of the American Medical Association, 1994, 271, 985-991.

44. Lynch T, Sano M, Marder KS, Bell KL, Foster NL, Defendini RF, Sima, AAF, Keohane C, Nygaard TG, Fahn S, Mayeaux R, Rowland LP, and Wilhelmsen KC. Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology, 1994, 44, 1878-1884.

45. Meyer M, Koeppe RA, Frey KA, Foster NL, and Kuhl DE. PET measure of benzodiazepine receptors in Alzheimer’s disease. Archives of Neurology, 1995, 52, 314-317.

46. Alexander NB, Mollo JM, Giordani B, Ashton-Miller JA, Schultz AB, Grunawalt JA, Foster NL. Maintenance of balance, gait patterns and obstacle clearance in Alzheimer’s disease. Neurology, 1995, 45, 908-914.

47. Minoshima A, Frey KA, Koeppe RA, Foster NL, and Kuhl DE. A diagnostic approach in Alzheimer’s disease using 3-dimensional stereotactic surface projections of fluorine-18-FDG PET. Journal of Nuclear Medicine, 1995, 36, 1238-1248.

48. Minoshima A, Frey KA, Foster NL, and Kuhl DE. Preserved pontine glucose metabolism in Alzheimer’s disease: a reference region for functional brain analysis. Journal of Computer Assisted Tomography, 1995, 19, 541-547.

49. McDaniel KD, Edland SD, Heyman A, and the CERAD Clinical Investigators. Relationship between level of insight and severity of dementia in Alzheimer disease. Alzheimer Disease and Associated Disorders, 1995, 9, 101-104.

50. Groom GN, Junck L, Foster NL, Frey KA, and Kuhl DE. Positron emission tomography of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer's disease. Journal of Nuclear Medicine, 1995, 36, 2207-2210.

51. Fontana RJ, Turgeon DK, Woolf TF, Knapp MJ, Foster NL, and Watkins PB. The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity. Hepatology, 1996, 23, 1429-1435.

52. Sima AAF, Defendini RF, Keohane C, D'Amato C, Foster NL, Parchi P, Gambetti P, Lynch T, and Wilhelmsen KC. The neuropathology of chromosome 17-linked dementia. Annals of Neurology, 1996, 39, 734-743.

53. Fisher NJ, Rourke BP, Bieliauskas L, Giordani B, Berent S, and Foster NL. Neuropsychological subgroups of patients with Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology, 1996, 18, 349-370.

54. Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T Gracon, S, and Tacrine Study Group. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology, 1996, 47, 166-177.

55. Butter CM, Trobe JD, Foster NL, and Berent S. Visual-spatial deficits explain visual symptoms in Alzheimer's disease. American Journal of Ophthalmology, 1996, 122, 97-105.

56. Murman DL, Foster NL, Kilgore SP, McDonagh CA, and Fink JK. Apolipoprotein E and Alzheimer's disease: strength of association is related to age of onset. Dementia, 1996, 7, 251-255.

57. Foster NL, Petersen RC, Gracon SI, Lewis K, and the Tacrine 970-6 Study Group. An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. Dementia, 1996, 7, 260-266.

58. Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, Wieland DM, and Koeppe RA. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease and Parkinson's disease. Annals of Neurology, 1996, 40, 399-410.

59. Cochran EJ, Bennett DA, Cervenáková L, Kenney K, Bernard B, Foster NL, Benson DF, Goldfarb LG, and Brown P. Familial Creutzfeldt-Jakob disease with a five-repeat octapeptide insert mutation. Neurology, 1996, 47, 727-733.

60. Sano M, Ernesto C, Klauber MR, Schafer K, Woodbury P, Thomas R, Grundman M, Growdon J, Thal LJ, and Members of the Alzheimer's Disease Cooperative Study. Rationale and design of a multicenter study of selegiline and a-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer Disease and Associated Disorders, 1996, 10, 132-140.

61. Sano M, Ernesto C, Thomas R, Klauber Mr, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ, for the Members of the Alzheimer’s Disease Cooperative Study. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. New England Journal of Medicine, 1997, 338, 1216-1222.

62. Vander Borght T, Minoshima S, Giordani B, Foster NL, Frey KA, Berent S, and Kuhl DE. Cerebral metabolic differences in Alzheimer's and Parkinson's diseases matched for dementia severity. Journal of Nuclear Medicine, 1997, 38, 797-802.

63. Foster NL, Wilhelmsen K, Sima AAF, Jones MZ, D'Amato C, and Gilman S. Participants in the Conference. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Annals of Neurology, 1997, 41, 706-715.

64. Morris JC, Ernesto C, Schafer K, Coats M, Leon S, Sano M, Thal LJ, Woodbury P, and the Alzheimer's Disease Cooperative Study. Clinical Dementia Rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology, 1997, 48, 1508-1510.

65. Murman DL, Giordani B, Mellow AM, Johanns JR, Little RJA, Hariharan M, and Foster NL. Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease. Neurology, 1997, 49, 153-161.

66. Minoshima S, Giordani BJ, Berent S, Frey KA, Foster NL, and Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Annals of Neurology, 1997, 42, 85-94.

67. Fisher NJ, Rourke BP, Bieliauskas LA, Giordani B, Berent S, and Foster NL. Unmasking the heterogeneity of Alzheimer's disease: case studies of individuals from distinct neuropsychological subgroups. Journal of Clinical and Experimental Neuropsychology, 1997, 19, 713-754.

68. Whall AL, Black ME, Groh CJ, Yankou DJ, Kupferschmid BJ, and Foster NL. The effects of natural environments on agitation and aggression in late stage dementia patients. American Journal Alzheimer’s Disease and Other Dementias, 1997, 12, 216-220.

69. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, Hyman BT, Crain B, Tang M, Phelps CH, and the Alzheimer's Disease Centers Consortium on APOE and Alzheimer's Disease. Utility of the APOE genotype in the diagnosis of Alzheimer's disease. New England Journal of Medicine, 1998, 338, 506-511.

70. Foster NL. The development of biological markers for the diagnosis of Alzheimer's disease. Neurobiology of Aging, 1998, 19, 127-129.

71. Whall AL, Black ME, Groh CJ, Yankou DJ, Kupferschmid BJ, and Foster NL. Efecto del entorno natural sobre la agitación y la agresión en pacientes con estado avanzado de demencia. Metas De Enfermeria, 1998, 12-18. [Reprint, In Spanish]

72. Minoshima S, Foster NL, Nishimura S, and Kuhl DE. Glucose metabolic imaging for functional diagnosis of brain disorders: current status and prospects. Japanese Journal of Radiology, 1998, 43, 1113-1121. [In Japanese].

73. Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M, for the Dementia Trialists' Collaboration. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Journal of the American Medical Association, 1998, 280, 1777-1782.

74. Fontana RJ, deVries TM, Woolf TF, Knapp MJ, Brown AS, Kaminsky LS, Tang B-K, Foster NL, and Watkins PB. Caffeine based measures of CYP1A2 activity predict the oral clearance of tacrine. British Journal of Clinical Pharmacology, 1998, 46, 221-228.

75. Bartok JA, Wilson CS, Giordani B, Keys BA, Persad CC, Foster NL, and Berent S. Varying patterns of verbal recall, recognition, and response bias with progression of Alzheimer's disease. Aging Neuropsychology and Cognition, 1998, 4, 266-71.

76. Whall AL, Black ME, Groh CJ, Yankou DJ, Kupferschmid BJ, and Foster NL. The effects of natural environments on agitation and aggression in late stage dementia patients. Journal of Healthcare Safety, Compliance and Infection Control, 1999, 3, 31-35. [Reprint]

77. Berent S, Giordani B, Foster NL, Minoshima S, Lajiness-O'Neal R, Koeppe R, and Kuhl DE. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. Journal of Psychiatric Research, 1999, 33, 7-16.

78. Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, Frey KA, and Kilbourn MR. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology, 1999, 52, 691-699.

79. Knopman DS, Berg JD, Thomas R, Grundman M, Thal LJ, Sano M, for Members of the Alzheimer's Disease Cooperative Study. Nursing home placement is related to dementia progression: experience from a clinical trial. Neurology, 1999, 52, 714-718.

80. Foster NL. Frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17): a clinician's guide. Neurologist, 1999, 5, 213-221.

81. Sima AAF, D'Amato C, and Foster NL. Neuropathology of chromosome-17-linked dementia. Dementia and Geriatric Cognitive Disorders, 1999, 10 (suppl 1), 61-63.

82. Whall AL, Black MEA, Yankou DJ, Groh CJ, Kupferschmid BJ, Foster NL, and Little R. Nurse aides' identification of onset and level of agitation in late stage dementia patients. American Journal of Alzheimer’s Disease and Other Dementias, 1999, 14, 202-206.

83. Foster NL, Minoshima S, Johanns J, Little R, Heumann ML, Kuhl DE, and Gilman S. PET measures of benzodiazepine receptors in progressive supranuclear palsy. Neurology, 2000, 54, 1768-1773.

84. Foster NL, Gombosi E, Teboe C, and Little RJA. Balanced centralized and distributed database design in a clinical research environment. Statistics in Medicine, 2000, 19, 1531-1544.

85. Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, and Koeppe RA. Limited donepezil inhibition of acetylcholinesterase measured with PET in living Alzheimer cerebral cortex. Annals of Neurology, 2000, 48, 391-395.

86. Teri L, Logsdon RG, Peskind E, Raskind M, Weiner M, Tractenberg RE, Foster NL, Schneider LS, Sano M, Whitehouse P, Tariot P, Mellow AM, Auchus AP, Grundman M, Thomas RG, Schafer K, Thal LJ, and Members of the Alzheimer's Disease Cooperative Study. Treatment of agitation in Alzheimer’s disease patients: a randomized placebo controlled clinical trial. Neurology, 2000, 55, 1271-1278.

87. Kluin KJ, Gilman S, Foster NL, Sima AAF, D'Amato C, Bruch LA, Bluemlein L, Little RJ, and Johanns J. Neuropathologic correlates of dysarthria in progressive supranuclear palsy. Archives of Neurology, 2001, 58, 265-269.

88. Zubieta JK, Koeppe RA, Frey KA, Kilbourn MR, Mangner TJ, Foster NL, and Kuhl DE. Assessment of muscarinic receptor concentrations in aging and Alzheimer's disease with [11C]NMPB and PET. Synapse, 2001, 39, 275-287.

89. Bozoki A, Giordani B, Heidebrink JL, Berent S, and Foster NL. Mild cognitive impairments predict dementia in non-demented elderly with memory loss. Archives of Neurology, 2001, 58, 411-416.

90. Connell CM, Shaw BA, Holmes SB, and Foster NL. Caregiver's attitudes toward participation in Alzheimer's disease research: implications for recruitment and retention. Alzheimer Disease and Associated Disorders, 2001, 15, 137-145.

91. Doody RS, Dunn JK, Clark CM, Farlow M, Foster NL, Liao T, Gonzales N, Lai E, and Massman P. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders, 2001, 12, 295-300.

92. Minoshima S, Foster NL, Sima AAF, Frey KA, Albin RL, and Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Annals of Neurology, 2001, 50, 358-365.

93. Foster NL. Barriers to treatment: the unique challenges for physicians providing dementia care. Journal of Geriatric Psychiatry and Neurology, 2001, 14, 188-198.

94. Lynch T, Sano M, Marder KS, Bell KL, Foster NL, Defendini RF, Sima AA, Keohane C, Nygaard TG, Fahn S, Mayeux R, Rowland LP, and Wilhelmsen KC. Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology, 2001, 57 Suppl 3, S39-S45.

95. Hong M, Shah GV, Adams KM, Turner RS, and Foster NL. Spontaneous intracranial hypotension causing reversible frontotemporal dementia. Neurology, 2002, 58, 1285-1287.

96. Minoshima S, Foster NL, Petrie EC, Albin RL, Frey KA, and Kuhl DE. Neuroimaging in dementia with Lewy bodies: metabolism, neurochemistry, and morphology. Journal of Geriatric Psychiatry and Neurology, 2002, 15, 200-209.

97. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas R, Thal L, for the Alzheimer's Disease Cooperative Study. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. Journal of the American Medical Association, 2003, 289, 2819-2826.

98. Foster NL. Validating FDG-PET as a biomarker for frontotemporal dementia. Experimental Neurology, 2003, 184 (Supplement 1), S2-S8.

99. Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, Thomas R, Thal LJ, for the Alzheimer’s Disease Cooperative Study. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer’s disease. Sleep, 2003, 26, 893-901.

100. Higdon R, Foster NL, Koeppe RA, DeCarli CS, Jagust WJ, Clark CM, Barbas NR, Arnold SE, Turner RS, Heidebrink JL, and Minoshima S. A comparison of classification methods for differentiating fronto-temporal dementia from Alzheimer’s disease using FDG-PET imaging. Statistics in Medicine, 2004, 23, 315-326.

101. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen P, Bennett DA, Foster NL, Jack C, Galasko D, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck C, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ, and the Alzheimer’s Disease Cooperative Study. Mild cognitive impairment can be distinguished from Alzheimer's disease and normal aging for clinical trials. Archives of Neurology, 2004, 61, 59-66.

102. Banaszak-Holl J, Fendrick AM, Foster NL, Herzog AR, Kabeto MU, Kent DM, Straus WL, and Langa KM. Predicting nursing home admission: estimates from a seven year follow-up of a nationally representative sample of older Americans. Alzheimer Disease and Associated Disorders, 2004, 18, 83-89.

103. Langa KM, Larson EB, Wallace RB, Fendrick AM, Foster NL, Kabeto MU, Weir DR, Willis RJ, and Herzog AR. Out-of-pocket health care expenditures among older Americans with dementia. Alzheimer Disease and Associated Disorders, 2004, 18, 90-98.

104. Moretti PM, Lieberman AP, Wilde E, Giordani B, Kluin KJ, Koeppe RS, Minoshima S, Kuhl DE, Seltzer WK, and Foster NL. Novel insertional presenilin 1 mutation causing AD with spastic paraparesis. Neurology, 2004, 62, 1865-1868.

105. Langa KM, Foster NL, Larson EB. Mixed Dementia: Emerging Concepts and Therapeutic Implications. JAMA 2004;292:2901-8.

106. Tasdizen T, Awate S, Whitaker R, Foster NL. MRI Tissue Classification with Neighborhood Statistics: A Nonparametric, Entropy-Minimizing Approach. Proceedings of the 8th International Conference on Medical Image Computing and Computer Assisted Intervention (MICCAI). 2005.

107. Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, Kukull WA. The Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data From Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006 Oct/Dec;20(4):210-216.

REVIEW ARTICLES

1. Foster NL. The clinical diagnosis of Alzheimer’s disease. Michigan Postgraduate Review,1991,8,107-113.2. Hong M, Shah GV, Adams KM, Turner RS, Foster NL. Spontaneous intracranial hypotension causing reversible

frontotemporal dementia. Dementia Review Series (Sweden), 2003, 5, 9-113. Langa KM, Foster NL, Larson EB. Mixed Dementia: emerging concepts and therapeutic implications. Journal of the

American Medical Association, 2004, 292, 2901-2908.

BOOKS & BOOK CHAPTERS

1. Chase TN, Foster NL, Fedio P, DiChiro G, Patronas NJ. Alzheimer’s disease: local cerebral metabolism studies using the fluoro-deoxyglucose-positron emission tomographic techniques. In: D Samuel, S Ageri, S Gershon, VE Grimm, and G Toffano, (Eds.), Aging of the Brain. New York: Raven Press, 1983, 43-154.

2. Chase TN, Foster NL, Fedio P, Mansi L, Brooks R, Kessler R, DiChiro G. Cognitive and cerebral metabolic function in early and advanced Alzheimer’s disease. In: C Fieschi, GL Lenzi, and CW Loeb, (Eds.), Effects of Aging on Regulation of Cerebral Blood Flow and Metabolism. Basel: Karger, 1984, 176-179.

3. Chase TN, Foster NL. Alterations in local cortical glucose metabolism in Alzheimer’s disease. In: NA Lassen, KA Hossmarin, M Reivich, A Agnoli, and J Cahn, (Eds.), Drugs and Diseases, 1984, Vol 1, Number 3. London: John Libbey Eurotex Ltd., 1984, 175-180.

4. Chase TN, Brooks RA, DiChiro G, Fedio P, Foster NL, Kessler RA, Mansi L, Manning RG, Patronas NJ. Focal cortical abnormalities in Alzheimer’s disease. In: T Greitz, DH Ingvar, and L Widen, (Eds.), The Metabolism of the Human Brain Studied with Positron Emission Tomography. New York: Raven Press, 1985, 433-440.

5. Foster NL, Chase TN. Huntington’s disease. In: RT Johnson, (Ed.), Current Therapy in Neurology Disease. Philadelphia: B. C. Decker, Inc., 1985, 244-247.

6. Foster NL. Age-related changes in the human nervous system. In: HG Mueller, VC Geoffrey, (Eds.), Communication Disorders in Aging: Assessment and Management. Washington D. C.: Gallaudet University Press, 1987, 3-35.

7. Foster NL. Brain imaging as a useful tool in the diagnosis of dementia. In: HJ Altman, BN Altman, (Eds.), Alzheimer’s and Parkinson’s Diseases. Recent Advances in Research and Clinical Management. New York: Plenum Press, 1989, 19-38.

8. Foster NL. Dementia in movement disorders. In: WRW Martin, (Ed.), Functional Imaging in Movement Disorders. Cleveland: CRC Press, 1990, 215-232.

9. Mayeux RP, Foster NL, Rossor M, Whitehouse PJ. Clinical evaluation of dementia. In: PJ Whitehouse, (Ed.), Dementia. Philadelphia: F. A. Davis Co., 1993, 92-129.

10. Foster NL. PET imaging. In: RD Terry, R Katzman, KL Bick, (Eds.), Alzheimer Disease. New York: Raven Press, 1994, 87-103.

11. Farlow MR, Brashear A, Hui S, Schneider L, Unverzagt F, Tacrine Study Group. The effects of tacrine in patients with mild versus moderate stage Alzheimer's disease. In: K Iqbal, JA Mortimer, B Winblad, HM Wisniewski, (Eds.), Research Advances in Alzheimer's Disease and Related Disorders. New York: John Wiley & Sons, Ltd., 1995, 283-292.

12. Minoshima S, Frey KA, Foster NL, Kuhl DE. Diagnostic application of PET in dementia. In: Y Ishii, Y Yonekura, Y Fujibayashi, N Sadato, (Eds.), Recent Advances in Biomedical Imaging. New York: Elsevier, 1997, 103-107.

13. Foster NL, Minoshima S, Kuhl DE. Brain imaging. In: RD Terry, R Katzman, KL Bick, SS Sisodia, (Eds.), Alzheimer Disease. 2nd ed. New York: Raven Press, 1999, 67-93.

14. Heidebrink JL, Foster NL. Dementia. In: SM Shah, KM Kelly, (Eds.), Emergency Neurology: Principles and Practice. New York: Cambridge University Press, 1999, 312-325.

15. Minoshima S, Foster NL, Cross DJ, Kuhl DE. PET investigations of dementia. In: N Tamaki, E Tsukamoto, Y Kuge, C Katoh, K Morita, (Eds.), Positron Emission Tomography in the Millennium: Proceedings of the International PET Symposium held in Hokkaido, Japan 24-26th September 1999. Amsterdam: Elsevier Science B. V., 2000, 17-22.

16. Bozoki A, Giordani B, Heidebrink JL, Berent S, Foster NL. Synopsis of: mild cognitive impairments predict dementia in non-demented elderly with memory loss. In: B Vellas, J Fitten, B Winblad, H Feldman, M Grundman, E Giacobini, A Kurz, (Eds.), Research and Practice in Alzheimer's Disease, Volume 6. Paris: Serdi, 2002, 43-47.

17. Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, Foster NL, Schneider LS, Sano M, Whitehouse P, Tariot P, Mellow AM, Auchus AP, Grundman M, Thomas RG, Schafer K, Thal L. J., and Members of the Alzheimer's Disease Cooperative Study. Treatment of agitation in Alzheimer's disease: an investigation of haloperidol, trazodone and behavior management techniques. In: B Vellas, J Fitten, B Winblad, H Feldman, M Grundman, E Giacobini, A Kurz, (Eds.), Research and Practice in Alzheimer's Disease, Volume 6. Paris: Serdi, 2002, 232-236.

18. Foster NL, Bozoki A, Minoshima S, Kuhl DE, Giordani B, Berent S. Isolated memory impairment: clues from imaging and follow-up studies. In: G Binetti, A Alberici, R Ghidoni, O Zanetti, (Eds.), The Shadow Line from Normal Aging to Dementia. Brecia: IRCCS Centro San Giovanni di Dio FBF, 2002, 27-35.

19. Foster NL. Neuropsychiatry of dementing disorders. In: BS Fogel, RB Schiffer, SM Rao. Neuropsychiatry, 2nd ed. New York: Lippincott, Williams and Wilkins, 2003, 1034-1070.

20. Foster NL. Neuroimaging techniques: CT, MRI, SPECT, PET. In: RW Richter, BZ Richter, (Eds.), Alzheimer's Disease: A Physician's Guide to Practical Management. Totowa, NJ: Humana Press Inc., 2004, 89-102.

21. Foster NL, Koeppe RE, Giordani BJ, Nichols TE, Lieberman AP. Variations of the phenotype in frontotemporal dementias. In: Cummings J, Hardy J, Poncet M, Christen Y, eds. Genotype - Proteotype - Phenotype Relationships in Neurodegenerative Diseases. Series: Research and Perspectives in Alzheimer's Disease. Berlin: Spinger-Verlag, 2005:139-52

22. Foster NL. The Clinical Issues. In: Herholz K, Perani D, Morris C (Eds.), The Dementias: Early Diagnosis and Evaluation. New York: Taylor & Francis, 2006, 1-31.

ABSTRACTS

1. Foster NL, Patronas NJ, DeLaPaz R, DiChiro G, Brooks R, Chase TN, Fedio P, DeNaro A, Durso R. PET studies of Alzheimer’s disease. Neurology, 1982, 32, A167.

2. LeWitt PA, Ward CD, Larsen TA, Raphaelson MI, Newman RP, Foster NL, Dambrosia J, Calne DB. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology, 1982, 32, A181.

3. Foster NL, Chase TN, Hare TA. THIP treatment of Huntington’s disease. Neurology, 1982, 32, A206.4. Newman RP, LeWitt PA, Raphaelson MI, Foster NL, Calne DB, Chase TN. Dystonia: therapy with dopaminergic

ergot derivatives. Annals of Neurology, 1982, 12, 82.5. Foster NL, Chase TN, Patronas NJ, Brooks RL, DiChiro G, Fedio P. Cerebral mapping of apraxia by positron

emission tomography in Alzheimer’s disease. Annals of Neurology, 1982, 12, 89.6. Foster NL, Chase TN. Diffuse involvement in progressive aphasia. Annals of Neurology, 1983, 13, 224.7. Foster NL, Hare TA, Chase TN. Spinal fluid GABA in Alzheimer’s disease. Neurology, 1983, 33 (Suppl 2), 68.8. Karson CN, Foster NL, LeWitt PA, Jeste DV, Newman RP, Bruno FS. Blink rates and disorders of movement.

Neurology, 1983, 33(Suppl 2), 129.

9. Foster NL, Newman RP, LeWitt PA, Gillespie MM, Chase TN, Larsen TA. Beta-blockade of parkinsonian tremor. Annals of Neurology, 1983, 14, 134.

10. Chase TN, Foster NL, Mansi L. Alzheimer’s disease and the parietal lobe. Lancet, 1983, ii, 225.11. Foster NL, Chase TN. Relative preservation of frontal glucose metabolism in early Alzheimer’s disease. Abstracts

– Society for Neuroscience, 1983, 9, 270.12. Grimes AM, Grady CL, Foster NL, Sunderland T. Performance of the SSW in Alzheimer’s disease. ASHA, 1983,

25, 134.13. Pikus AT, Vernon EK, Grady CL, Foster NL, Sunderland T. Audiologic profile in Alzheimer’s disease. ASHA, 1983,

25, 134.14. Foster NL, Cox C, Harland AL, Fedio P, Chase TN. Vasopressin in Alzheimer’s disease (Reply). Neurology, 1983,

33, 1635.15. Bruno G, Foster NL, Fedio P, Mohr E, Cox C, Gillespie MM, Chase TN. THIP therapy of Alzheimer’s disease.

Neurology, 1984, 34(Suppl 1), 225.16. Foster NL, Tamminga CA, O’Donohue TL, Chase TN. PET-directed study of neuropeptide Y in Alzheimer’s

disease. Abstracts – Society for Neuroscience, 1984, 10, 173.17. Martin A, Bouwers P, Lalonde F, Cox C, Foster NL, Chase TN, Fedio F. Subgroups of Alzheimer’s patients:

neuropsychological and cerebral metabolic profiles. Abstracts – Society for Neuroscience, 1984, 10, 310.18. Tamminga CA, Tanimoto K, Foster NL, Chase TN. Alzheimer’s disease: somatostatin loss in area of maximal

fluorodeoxyglucose reduction. Neurology, 1985, 35(Suppl 1), 183.19. Sheridan PH, Sato S, Foster NL, Bruno G, Fedio P, Chase TN. Alpha background and parietal lobe function

(positron emission tomography, psychometry) in Alzheimer’s disease. Electroencephalography and Clinical Neurophysiology, 1985, 61, 33P.

20. Foster NL, VanDerSpek A, Sackellares JC, Aldrich MS, Hichwa RH, Gilman S, Agranoff BW. The effect of diazepam sedation on cerebral glucose metabolism in Alzheimer’s disease. Abstracts – Society for Neuroscience, 1985, 11, 1126.

21. Foster NL, Gilman S, Hichwa RD. Comparison of brain metabolism in Alzheimer’s disease and progressive supranuclear palsy using 18-F-fluoro-2-deoxyglucose positron emission tomography. Presented at the Michigan Neurological Association 18th Annual Meeting, Detroit, November 16, 1985.

22. Tamminga CA, Foster NL, Chase TN. Reduced brain somatostatin levels in Alzheimer’s disease. New England Journal of Medicine, 1985, 313, 1294-1295.

23. Foster NL, Chase TN. Cerebral metabolic rate of glucose and Alzheimer’s disease. Journal of Cerebal Blood Flow and Metabolism, 1986, 6, 125.

24. Foster NL, Gilman S, Berent S, Hichwa RD. Distinctive patterns of cerebral cortical glucose metabolism in progressive supranuclear palsy studied with positron emission tomography. Neurology, 1986, 36(Suppl 1), 338.

25. Wilt JL, Foster NL, Hutchins GD, Rothman ED, Rothley JM, Hichwa RD. A comparison of arterial versus arteriovenous sampling in the measurement of glucose metabolism by positron emission tomography. Clinical Research, 1986, 34, 1011A.

26. Townsend J, Foster NL, Siegel GJ. Cerebrotendinous xanthomatosis: diagnostic strategies in the patient with normal plasma cholestanol levels. Presented at the Michigan Neurological Association 19th Annual Meeting, Detroit, November 25, 1986.

27. Foster NL, Berent S, Brown MB, Gilman S, Hichwa RD. Cerebral cortical metabolism reflects performance on the Wechsler adult intelligence scale. Neurology, 1987, 37(Suppl 1), 169.

28. Berent S, Foster NL, Gilman S, Hichwa R, Lehtinen S. Patterns of cortical 18-F-FDG metabolism in Alzheimer’s and progressive supranuclear palsy patients are related to the types of cognitive impairments. Neurology, 1987, 37(Suppl 1), 172.

29. Foster NL, Gilman S, Berent S, Brown MB, Hichwa RD. Glucose hypometabolism in progressive supranuclear palsy not limited to frontal cortex. Annals of Neurology, 1987, 22, 123.

30. Townsend J, Foster NL, Siegel GJ, Salen G, Sadowsky M, Berginer VM. Psychiatric manifestations of cerebrotendinous xanthomatosis. Annals of Neurology, 1987, 22, 134.

31. Mountz JM, Foster NL, Ackermann RJ, Petry NA, Kuhl DE. Utility of Tc-99m HM PAO in evaluation of stroke. Radiology, 1987, 165(Suppl), 244.

32. Foster NL, Hansen MS, Siegel GJ, Kuhl DE. Mesial and lateral temporal glucose metabolism in aging and Alzheimer’s disease studied by PET. Neurology, 1988, 3(Suppl 1), 133.

33. Foster NL, Morin EM, Kuhl DE, Gilman S. Glucose metabolic activity in the basal ganglion and thalamus differs in progressive supranuclear palsy and Alzheimer’s disease. Neurology, 1988, 38(Suppl 1), 369.

34. Mountz JM, Foster NL, Stafford-Schuck KA, Ackermann RJ, Petry NA, Kuhl DE. Stroke prognosis using 99mTc HM PAO SPECT. Journal of Nuclear Medicine, 1988, 29(Suppl 1), 743.

35. Koeppe RA, Foster NL, Rothley JM, Kuhl DE. Determination of rate constants from dynamic FDG PET studies in degenerative brain disorders. Journal of Nuclear Medicine, 1988, 29(Suppl 1), 915.

36. Stafford-Schuck KA, Mountz JM, Foster NL, Ackermann RJ, Petry NA, Kuhl DE. Stroke prognosis using 99mTc-HM-PAO SPECT. Journal of Nuclear Medicine Technology, 1988, 16, A65.

37. Aldrich MS, Foster NL, White RF, Bluemlein LA, Prokopowicz G. Sleep abnormalities in progressive supranuclear palsy. Journal of Sleep Research, 1988, 17, 271.

38. Hansen MS, Foster NL, Siegel GJ, Berent S, Kuhl DE. Mesial and lateral temporal lobe glucose metabolism in aging. Clinical Research, 1988, 36, 921A.

39. Junck L, Moen JG, Foster NL, Gilman S, Kuhl DE. Cerebellar metabolic asymmetry in degenerative neurological disorders studied with PET. Neurology, 1989, 39(Suppl 1), 164.

40. Junck L, Moen JG, Bluemlein L, Foster NL, Agranoff BW, Gilman S, Young AB, Rothley JR, Betley AT, Koeppe RA, Hutchins G, Hichwa RD, Berent S, Kuhl DE. Cerebral glucose metabolism in normal aging studied with PET. Journal of Cerebal Blood Flow and Metabolism, 1989, 9(Suppl 1), S524.

41. Kuhl DE, Koeppe RA, Foster NL, Agranoff BW, Buchtel HA, Mountz JM. Cerebral perfusion, metabolic, and transport relations in Alzheimer’s and parkinsonian dementia. Journal of Cerebal Blood Flow and Metabolism, 1989, 9(Suppl 1), S525.

42. Mountz JM, Modell JG, Foster NL, DuPree ES, Ackerman RJ, Petry N, Bluemlein LE, Kuhl DE: Prognosis in stroke using the comparison of CT and 99mTc-HM-PAO SPECT. Journal of Cerebal Blood Flow and Metabolism, 1989, 9(Suppl 1), S718.

43. Koeppe R, Foster NL, Kuhl D. Tissue atrophy alone cannot explain parietal hypometabolism in PET studies of Alzheimer’s disease. Journal of Nuclear Medicine, 1989, 30, 895.

44. Mountz JM, Modell JG, Foster NL, DuPree ES, Ackerman RJ, Petry NA, Kuhl DE. A model for outcome-prediction following stroke using the comparison of CT and HM-PAO SPECT. Journal of Nuclear Medicine, 1989, 30, 895.

45. Foster NL, Mann U, Mohr E, Sunderland T, Katz D, Chase TN. Focal cerebral glucose hypometabolism in definite Alzheimer’s disease. Annals of Neurology, 1989, 26, 132-133.

46. Foster NL, Gilman S, Morin E, Markel D, Berent, S. The pattern of cerebral hypometabolism studied with positron emission tomography is similar in sporadic and familial Alzheimer’s disease. Annals of Neurology, 1989, 26, 135.

47. Brenner HM, Foster NL, Amato D, Koeppe RA, Gilman S, Kuhl DE. The ratio of cerebral glucose metabolism to cerebral blood flow in aged normal subjects and in Alzheimer’s disease. Clinical Research, 1989, 37, 973A.

48. Hansen MS, Foster NL, Judge F, Berent S. Cerebral glucose metabolism in a patient with neurosyphilis and response to treatment. Clinical Research, 1989, 37, 974A.

49. Butter CM, Trobe JD, Foster NL, Berent S. A new brief battery of tests for the detection of focal visuospatial deficits in the early stages of Alzheimer’s disease. Journal of Clinical and Experimental Neuropsychology, 1990, 12, 21-22.

50. Kluin KJ, Foster NL, Gilman S, Berent S. Speech disorders in progressive supranuclear palsy. Neurology, 1990, 40(Suppl 1), 424.

51. Jones MZ, Douglass R, Fratkin JD, Foster NL, D’Amato CJ, Izenson SB, Dingeldey CJ, Goodman CB, Beane GE, Dementia postmortem examination program: interim recommendations for Michigan. Journal of Neuropathology and Experimental Neurology, 1990, 49, 307.

52. Chen JW, Foster NL, Berent S, Mountz JM. Single photon emission computed tomography with N-isopropyl-(I-123)p-iodoamphetamine (IMP-SPECT) fails to differentiate progressive from non-progressive dementia. Journal of the American Geriatrics Society, 1990, 38, A28.

53. Hermanowicz NS, Penney JB, Foster NL, Shoulson I. Muscarinic receptors in basal ganglia of progressive supranuclear palsy. Abstracts – Society for Neuroscience, 1990, 16, 1120.

54. Kluin KJ, Foster NL, Gilman S, Berent S. Speech disorders in progressive supranuclear palsy. ASHA, 1990, 32, 122.

55. Jones MZ, Fratkin JD, Foster NL, D’Amato CJ, Lovell KL, Koestner A, Huang E. Michigan dementia postmortem examination program: interim recommendations for standardization of the neuropathology examination. Presented at the XIth International Congress of Neuropathology, Kyoto, Japan, September 2-8, 1990.

56. Boivin MJ, Giordani B, Berent S, Amato DA, Lehtinen S, Koeppe RA, Buchtel HA, Foster NL, Kuhl DE. Verbal fluency and positron emission tomographic mapping of regional cerebral glucose metabolism. Journal of Clinical and Experimental Neuropsychology, 1991, 13, 80-81.

57. Foster NL, Giordani B, Mellow A, Aronson S, Berent S. Memory effects of low dose ketamine in Alzheimer’s disease. Neurology, 1991, 41(Suppl 1), 214.

58. Foster NL, Frey KA, Buck A, Giordani BJ, Berent S, Kuhl DE. Tacrine therapy does not alter cerebral muscarinic receptors. Presented at the Second International Springfield Symposium on Advances in Alzheimer’s Therapy, May 4, 1991.

59. Lee KS, Frey KA, Koeppe RA, Buck A, Mulholland GK, Foster NL, Kuhl DE. Quantification of muscarinic cholinergic receptors in aging and Alzheimer’s disease. Journal of Nuclear Medicine, 1991, 32, 942-943.

60. Chen JW, Foster NL, Giordani B, Harris J, Koeppe RA, Berent S, Kuhl DE. The relationship of Mini-Mental State examination (MMSE) and cerebral glucose metabolism in Alzheimer’s disease. Journal of the American Geriatrics Society, 1991, 39, A44.

61. Giordani B, Berent S, Koeppe RA, Foster NL, Buchtel HA, Kuhl DE, Frey KA, Lehtinen SJ. PET-FDG cerebral metabolic indices of memory impairment. Biological Psychiatry, 1991, 29, 683S.

62. Fratkin JD, Jones MZ, D’Amato CJ, Foster NL, Remick D, Dragovic L, Garcia JH, Ho KL, Huang TE, Sima A, Lovell K. Michigan Dementia postmortem examination program: neuropathological efforts towards morphological standardization of dementia diagnoses. Journal of Neuropathology and Experimental Neurology, 1991, 50, 300.

63. D’Amato CJ, Sima AF, Foster NL, Dickson DW, Hicks SP. Cerebral Lewy bodies with progressive supranuclear palsy. Journal of Neuropathology and Experimental Neurology, 1991, 50, 308.

64. Axelrod BN, Goldman RS, Giordani BJ, Foster NL, Berent S. Longitudinal stability of the Fuld cholinergic profile in Alzheimer’s disease. Journal of Clinical and Experimental Neuropsychology, 1992, 14, 21.

65. Foster NL, Gilman S, Gelb DJ, Struble L, Giordani B, Berent S, Lohman M. Extrapyramidal signs in probable Alzheimer’s disease. Neurology, 1992, 42(Suppl 3), 215S.

66. Meyer MA, Koeppe RA, Frey KA, Foster NL, Kuhl DE. Benzodiazepine receptors are unaltered in hypometabolic parietal cortex in Alzheimer’s disease. Journal of Nuclear Medicine, 1992, 33, 887.

67. Fratkin J, Remick D, D’Amato C, Hogan J, Shope J, Izenson S, Foster N, Huang T, Dragoc L, Garrein J, Ho K, Sima A, Lovell K, Jones M. Michigan postmortem examination network for dementia patients. Journal of Neuropathology and Experimental Neurology, 1992, 51, 315.

68. D’Amato CJ, Foster NL, Hicks SP, Sima AAF. Swollen cortical neurons and Lewy bodies accompanying progressive supranuclear palsy and Creutzfeldt-Jakob disease. Journal of Neuropathology and Experimental Neurology, 1992, 51, 324.

69. Giordani B, Berent S, Koeppe R, Foster N, Buchtel H, Boivin K, Frey K, Kuhl D. Memory and cerebral metabolism in Parkinson’s disease. Journal of Clinical and Experimental Neuropsychology, 1992, 14, 60-61.

70. Krishnan S, Foster NL, Trobe JD, Butter CM, Kuhl DE. Visual impairments in patients with Alzheimer’s disease correlate with reduced metabolism in visual association cortex measured by PET. Journal of the American Geriatrics Society, 1992, 40, SA13.

71. Sano M, Morris J, Thal L, Members of Alzheimer’s Disease Cooperative Study. Developing outcome measures for clinical trials by the Alzheimer’s Disease Cooperative Study (ADCS): standardized training for the clinical rating (CDR), initial results. Neurology, 1993, 43, A291.

72. Mellow AM, Foster NL, Aronson SM, Giordani B, St. Laurent RT, Berent S. Behavioral effects of the NMDA antagonist, ketamine, in Alzheimer’s disease. Biological Psychiatry, 1993, 33, 142A.

73. Wolf FM, Sharpe PA, Robins LS, Zweiffler AJ, Shope JT, Foster NL. Development of an early stage dementia helping relationship inventory. Professions Education Researcher Quarterly, 1993, 14, 11.

74. Groom GN, Koeppe RA, Foster NL, St. Laurent R, Giordani BJ, Kuhl DE. The effect of age of onset on regional cerebral glucose metabolism in Alzheimer’s disease. Journal of Nuclear Medicine, 1993, 34, 4P.

75. Groom GN, Junck L, Foster NL, Frey KA, Kuhl DE. Positron emission tomography of [C-11]PK 11195 binding to peripheral benzodiazepine receptors in Alzheimer’s disease. Journal of Nuclear Medicine, 1993, 34, 116P.

76. Hara M, Minoshima S, Foster NL, Kuhl DE. Is regional cerebral blood flow coupled with glucose metabolism in Alzheimer’s disease? Journal of Nuclear Medicine, 1993, 34, 116P.

77. Morgan MC, McCune WJ, Foster NL, Brunberg J, Berent S, Kuhl D. Correlations between positron emission tomography (PET) and magnetic resonance imaging (MRI) in lupus patients with and without dementia. Arthritis and Rheumatism, 1993, 36, S87.

78. Holmes SB, Foster NL, Connell CM. Satellite diagnostic and treatment centers: evaluation of a staff training program. Gerontologist, 1993, 33(special issue 1), 198.

79. Zubieta JK, Frey KA, Koeppe RA, Kilbourn MR, Mulholland GK, Foster NL, Kuhl DE. Muscarinic receptor binding in aging and Alzheimer’s disease determined with [C-11]N-methyl-4-piperidyl benzilate and PET. Journal of Nuclear Medicine, 1994, 35, 20P.

80. Murman DL, Frey KA, Knesper DJ, Giordani B, Berent S, Kuhl DE, Foster NL. Clinical and neuropsychometric predictors of progression in patients with complaints of memory loss. Annals of Neurology, 1994, 36, 311.

81. Minoshima S, Foster NL, Kuhl DE. Posterior cingulate cortex in Alzheimer’s disease. Lancet, 1994, 344, 895.82. Sima AAF, D’Amato C, Defendini RF, Jones MZ, Foster NL, Lynch T, Wilhelsen KC. Primary limbic lobe gliosis:

familial and sporadic cases. Brain Pathology, 1994, 4, 438.83. Wilhelmsen KC, Lynch T, Neystat M, Nygaard TG, Bernstein M, Marder KS, Mayeaux R, Fahn S, Rowland LP,

Foster NL, Wszolek Z, Keohan K, Sima AAF, Defendini RF. Clinical, pathologic and genetic analysis of familial disinhibition-dementia-parkinsonism-amyotrophy complex: a possible clue to the etiology of atypical dementias. Presented at the 4th International Conference on Alzheimer’s and Related Disorders, Minneapolis, Minnesota, 1994.

84. Roper BL, Giordani B, Berent S, Persad CC, Bieliauskas LA, Holleran K, Foster NL, Gilman S. Relationship of cognitive impairment and depression in motor disabilities in Parkinson’s disease. Journal of the International Neuropsychological Society, 1995, 1, 153.

85. Bartok JA, Wilson CS, Giordani B, Keys BA, Foster NL, Persad CC, Berent S. Patterns of recall and recognition deficits dependent on Alzheimer’s disease severity. Journal of the International Neuropsychological Society, 1995, 1, 161.

86. Murman DL, Giordani B, Mellow AM, Johanns JR, Little RJA, Foster NL. Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington’s disease. Neurology, 1995, 45, A253.

87. Sano M, Growdon J, Klauber M, Ernesto C, Schafer K, Woodbury P, Grundman M, Thal L, Alzheimer’s Disease Cooperative Study. Expanding the severity range of patients in clinical trials for Alzheimer’s disease: a multicenter clinical trial of selegiline and a-tocopherol. Neurology, 1995, 45(Suppl 4), A289.

88. Sima AAF, D’Amato C, Foster NL, Lynchj T, Defendini R, Wilhelmsen KC. Neuronal and glial inclusions in familial progressive limbic lobe sclerosis. Journal of Neuropathology and Experimental Neurology, 1995, 54, 459.

89. Berent S, Giordani B, Minoshima S, Foster NL, Koeppe RA, Kuhl DE. Isolated Memory Impairment (IMI): relationship to cognition, brain metabolism and Alzheimer’s disease. Journal of Cerebal Blood Flow and Metabolism, 1995, 15, S102.

90. Kuhl DE, Fessler JA, Minoshima S, Frey KA, Foster NL, Ficaro EP, Wieland DM, Koeppe RA. In vivo mapping of the vesicular acetylcholine transporter in aging and Alzheimer’s disease. Journal of Cerebal Blood Flow and Metabolism, 1995, 15, S132.

91. Minoshima S, Foster NL, Frey KA, Kuhl DE. Abnormal energy metabolism in the cingulate cortex in Alzheimer’s disease. Journal of Cerebal Blood Flow and Metabolism, 1995, 15, S790.

92. Foster NL, Minoshima S, Kuhl DE, Sima AAF. Metabolic topography of progressive limbic lobe sclerosis. Journal of Cerebal Blood Flow and Metabolism, 1995, 15, S818.

93. Buchtel HA, Koeppe RA, Mountz J, Foster NL, Berent S, Giordani B, Kuhl DE. Cerebral blood flow changes in response to visual stimulation in demented patients. Abstracts – Society for Neuroscience, 1995, 21, 1488.

94. Sano M, Ernesto C, Klauber M, Schafer K, Woodbury P, Grundman M, Thal L, Alzheimer's Disease Cooperative Study. Using the ADAS to assess change among moderately and severly impaired AD patients. Journal of the International Neuropsychological Society, 1996, 2, 13.

95. Bartok JA, Wilson CS, Giordani B, Foster N, Berent S. Longitudinal investigation of response bias, recall and recognition in Alzheimer's disease. Journal of the International Neuropsychological Society, 1996, 2, 13.

96. Fisher NJ, Rourke BP, Bieliauskas L, Giordani B, Berent S, Foster NL. Neuropsychological subgroups of patients with Alzheimer's disease. Journal of the International Neuropsychological Society, 1996, 2, 30.

97. Gilman S, Foster NL. The Alzheimerization of aging. Gerontologist, 1996, 36, 9-10.98. Sano M, Growdon J, Thomas R, Ernesto C, Schafer K, Woodbury P, Grundman M, Thal L, Alzheimer's Disease

Cooperative Study. Evaluation of efficacy measures in clinical trials for Alzheimer's disease: does psychometric test performance predict clinically relevant outcomes? Neurology, 1996, 46, A218.

99. Galasko D, Bennett D, Ernesto C, Thomas R, Sano M, Alzheimer's Disease Cooperative Study. Development of a pool of items to assess activities of daily living in clinical trials for Alzheimer's disease. Neurology, 1996, 46, A248.

100. Foster NL, Sima AAF, D'Amato C, Bruch LA, Kluin K, Bluemlein LA, Little RJ, Johanns J, Gilman S. Cerebral cortical pathology in progressive supranuclear palsy is correlated with severity of dementia. Neurology, 1996, 46, A363.

101. Grundman M, Petersen RC, Ernesto C, Galasko D, Sano M, Thal LJ, the ADCS Cooperative Study. Rate of Dementia of the Alzheimer Type (DAT) in subjects with mild cognitive impairment. Neurology, 1996, 46, A403.

102. Minoshima S, Frey KA, Giordani BL, Foster NL, Koeppe RA, Berent S, Albin RL, Kuhl DE. Technical feasibility and initial diagnostic application of functional brain image database system in dementia. Journal of Nuclear Medicine, 1996, 37, 163P.

103. Minoshima S, Giordani BL, Berent S, Frey KA, Foster NL, Kuhl DE. The posterior cingulate cortex: the earliest metabolic reduction in Alzheimer's disease as revealed by PET. Journal of Nuclear Medicine, 1996, 37, 164P.

104. Sima AAF, Foster N, Jones MZ, D'Amato C, Boyer P.F. Mesocorticolimbic dementia: DLBD without Lewy bodies or a separate entity? Journal of Neuropathology and Experimental Neurology, 1996, 55, 609.

105. Hariharan M, Murman DL, Foster NL. A new sensitive, simple and reproducible liquid chromatographic ultraviolet detector method for the analysisi of human plasma ketamine and norketamine concentrations. Presented at the XVIth International Conference of Clinical Chemistry, London, England, July 8-12, 1996.

106. Foster NL, Fitzgerald J, Remick DGJ. Letter to the Editor. Gerontology News, 1996, 2.107. Heidebrink JL, Gombosi E, Cornellier DS, LeWitt PA, Foster NL. Do satellite diagnostic and treatment centers

overcome referral bias in dementia research? Annals of Neurology, 1996, 40, 502.108. Heidebrink JL, Foster NL, for the Michigan Dementia Postmortem Network. Demographic and postmortem

differences between Alzheimer's disease in the community and at an academic referral center. Presented at the 7th Annual Michigan Neuropathology Day, Ann Arbor, MI, October 26, 1996.

109. Whall A, Black M, Yankou D, Groh C, Foster N. Effects of natural elements upon agitation in dementia. Gerontologist, 1996, 36(Special Issue 1), 23-24.

110. Giordani B, Persad CC, Mesmer C, Sima AAF, Gilman S, Albin RL, Foster NL, Heumann ME, Kluin K, Berent S. Lewy body disease differs from Alzheimer’s disease in neuropsychological profile. Journal of the International Neuropsychological Society, 1997, 3, 15.

111. Gilman S, Foster NL, Minoshima S, Koeppe RA, Martorello SP, Heumann ML, Kuhl DE. Benzodiazepine receptor density in progressive supranuclear palsy studies with [11C]flumazenil and PET. Movement Disorders, 1997, 12(suppl 1), 78.

112. Kluin DJ, Gilman S, Foster NL, Sima AAF, D’Amator C, Bruch LA, Bluelein L, Little RJ, Johanns J. Degeneration of substantia nigra pars compacta contributes to the dysarthria of PSP. Neurology, 1997, 48(Suppl 2), A97.

113. Minoshima S, Foster NL, Frey KA, Wahl RL, Burdette JH, Kuhl DE. Can FDG PET distinguish dementia patients with cortical Lewy bodies from pure Alzheimer's disease? Journal of Nuclear Medicine, 1997, 38(Suppl), 70P-71P.

114. Minoshima S, Foster NL, Frey KA, Albin RL, Sima AAF, Berent S, Kuhl DE. Metabolic differences in Alzheimer's disease with and without cortical Lewy bodies as revealed by PET. Journal of Cerebal Blood Flow and Metabolism, 1997, 17(Suppl 1), S437.

115. Foster NL, Minoshima S, Sima AAF, Kuhl DE. Variability of cerebral glucose metabolic patterns in Alzheimer's disease can not be explained by coexistent disorders. Journal of Cerebal Blood Flow and Metabolism, 1997, 17(Suppl 1), S578.

116. Heidebrink JL, Millett SL, Jones MZ, Foster NL, for the Michigan Dementia Postmortem Network. Differences between Alzheimer's disease in the community and at an academic referral center. Journal of Neuropathology and Experimental Neurology, 1997, 56, 618.

117. Fisher NJ, Rourke BP, Bieliauskas LA, Giordani B, Berent S, Foster N. Neuropsychological subgroups of patients with Alzheimer's disease: case presentations. Canadian Psychology, 1997, 38, 10.

118. Gilman S, Foster NL, Koeppe RA, Kilbourn MR, et al. Striatal monoaminergic presynaptic terminals in Alzheimer's disease studied with (+)[11C]dihydrotetrabenazine and positron emission tomography. Journal of the Neurological Sciences, 1997, S150, S21.

119. Heidebrink JL, Minoshima S, Giordani B, Mellow AM, Johanns JR, Little RJA, Foster NL. Behavioral effects of ketamine can not be explained by cingulate activation. Annals of Neurology, 1997, 42, 403.

120. Heidebrink JL, Giordani B, Mellow AM, Johanns JR, Little RJA, Foster NL. Phenobarbital does not reduce the adverse effects of low-dose ketamine. Annals of Neurology, 1997, 42, 403.

121. Heidebrink JL, Foster NL. Alzheimer's disease is particularly underreported in women and minorities. Gerontologist, 1997, 37 (Special Issue 1), 22-23.

122. Fisher NJ, Rourke BP, Bieliauskas LA, Foster NL. External validation of distinct neuropsychological subgroups of Alzheimer's disease patients: preliminary findings from the CERAD data. Journal of the International Neuropsychological Society, 1998, 4, 30.

123. Lajiness-O'Neill R, Giordani B, Berent S, Minoshima S, Foster N, Koeppe R, Kuhl D. Paradoxical increase in frontal cerebral glucose utilization in isolated memory impairment at a two-year follow-up: relationship to neuropsychological functioning. Journal of the International Neuropsychological Society, 1998, 4, 44.

124. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. [F-18]FDG PET predicts the development of Alzheimer's disease in memory impaired patients without dementia. Journal of Nuclear Medicine, 1998, 39, 96P.

125. Nishimura S, Minoshima S, Giordani B, Johanns J, Little RJA, Foster NL, Kuhl DE. Predicting cognitive decline in Alzheimer's disease using positron emission tomography. Journal of Nuclear Medicine, 1998, 39, 96P.

126. Foster NL, Sima AAF, Minoshima S, Kuhl DE. Clinical and neuropathological correlations with PET in FTDP-17 and sporadic frontal dementia. Neurobiology of Aging, 1998, 19, S296.

127. Doody R, Clark C, Farlow M, Foster N, Gonzales N, Liao J, Lai E, Massman P. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer’s disease patients. Neurobiology of Aging, 1998, 19, S303.

128. Shaw BA, Connell CM, Holmes SB, Foster NL. Attitudes toward participation in Alzheimer’s disease research among family caregivers. Gerontologist, 1998, 38 (Special Issue 1), 388.

129. Bozoki A, Giordani B, Heidebrink JL, Carr JM, Foster NL, Berent S. Relevance of mild cognitive impairments to prediction of Alzheimer's disease among isolated memory Impairment patients. Neurology, 1999, 52 (Suppl 2), A386.

130. Foster NL, Moura V, Gelb DJ, Sima AAF. Consensus clinical criteria have limited ability to distinguish dementia with Lewy bodies and Alzheimer’s disease. Neurology, 1999, 52 (Suppl 2), A476.

131. Minoshima S, Kuhl DK, Cross DJ, Buchtel HA, Pennell PB, Giordani B, Berent S, Foster NL, Ross DA, Henry TR. Does the entorhinal pathology explain the discordance between glucose metabolic and pathologic changes in very early Alzheimer's disease? Journal of Cerebal Blood Flow and Metabolism, 1999, 19(Suppl 1), S4.

132. Berent S, Giordani B, Minoshima S, Foster NL, Koeppe RA, Kuhl DE. Psychological disturbance and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. Journal of Cerebal Blood Flow and Metabolism, 1999, 19(Suppl 1), S21.

133. Foster NL, Hickenbottom SL. When do strokes cause dementia? Archives of Neurology, 1999, 56, 778-779 (editorial).

134. Minoshima S, Cross DJ, Foster NL, Henry TR, Kuhl DE. Discordance between traditional pathologic and energy metabolic changes in very early Alzheimer's disease: pathophysiological implications. Annals of the New York Academy of Sciences, 1999, 893, 350-352.

135. Foster NL, Moura V, Giordani B, Minoshima S, Kuhl DE. Frontal hypometabolism in mild Alzheimer's disease is associated with more rapid progression of dementia. Neurobiology of Aging, 2000, 21, S108.

136. Makoni S, Ferreira M, Foster NL. Investigating linguistic and cultural constructions of late-life dementias in urban black Africans. Neurobiology of Aging, 2000, 21, S170.

137. Moretti PM, Giordani B, Kluin KJ, Minoshima S, Kuhl DE, Seltzer WK, Foster NL. Early-onset familial Alzheimer's disease and spastic paraparesis associated with a novel insertional mutation of the presenilin 1 gene. Neurobiology of Aging, 2000, 21, S175.

138. Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA. Reply to: "Central acetylcholinesterase inhibition in Alzheimer patients". Annals of Neurology, 2001, 49, 416-417.

139. Minoshima S, Cross DJ, Foster NL, Henry TR, Kuhl DE. Metabolic and pathologic discordance in very early Alzheimer's disease: pathophysiological implications. Neurobiology of Aging, 2001, 22, 340.

140. Langa KM, Kabeto M, Herzog AR, Foster N, Straus W, Fendrick AM. Dementia and psychiatric illness as predictors of nursing home admission: results from a nationally representative sample of U.S. elderly. Journal of General Internal Medicine, 2001, 16(Suppl 1), 150.

141. Murrell JR, Miravalle L, Foster NL, Albin R, Takao M, Ghetti B. Early-onset familial Alzheimer disease from the first American report: a presenilin-1 (PS1) mutation found in descndents. Journal of Neuropathology and Experimental Neurology, 2001, 60, 543.

142. Kluin KJ, Gilman S, Foster NL, D'Amato C, Bluemlein L, Little RJ, Sima AAF, Bruch LA, Johanns J. Reply to: "Neuropathologic correlates of dysarthria in progressive supranuclear palsy". Archives of Neurology, 2001, 58, 1500.

143. Barbas N, Foster NL. Social and ethical issues in the care of patients with dementia [editorial]. Journal of Geriatric Pscyhiatry and Neurology, 2001, 14, 167.

144. Hong M, Shah GV, Adams KM, Turner RS, Foster NL. Spontaneous intracranial hypotension causing reversible frontotemporal dementia. Neurology, 2002, 58(Suppl 3), A380.

145. Foster NL, Poynter JA, Heidebrink JL, Jagust WJ, Clark CM, Turner RS, Barbas NR, Arnold SE, DeCarli C, Koeppe RA, Higdon R, Minoshima S. Good diagnostic inter-rater reliability in a multicenter study of FDG-PET in the evaluation of dementia. Neurology, 2002, 58(Suppl 3), A401.

146. Peltier AC, Reading PH, Beydoun A, Edwards J, Gambetti P, Foster NL. Two concurrent cases of early-onset sporadic Creutzfeldt-Jakob disease in Michigan. Neurology, 2002, 58(Suppl 3), A442.

147. Bozoki A, An HG, Foster NL, Giordani B, Little RJA. Are there cognitive plateaus in Alzheimer's disease? Neurobiology of Aging, 2002, 23, S40.

148. Langa K, Herzog AR, Foster N, et al. Out-of-pocket health care expenditures among elderly individuals with dementia in the United States. Neurobiology of Aging, 2002, 23, 171.

149. Foster NL, Heidebrink JL, Clark CM, et al. Inter-rater reliability and diagnostic accuracy of FDG-PET is superior to clinical history and examination in dementia. Neurobiology of Aging, 2002, 23, S353.

150. Aisen PS, Schafer K, Grundman M, Farlow M, Sano M, Jin S, Thomas R, Thal L, for the Alzheimer's Disease Cooperative Study. Results of a mulitcenter trial of rofecoxib and naproxen in Alzheimer's disease. Neurobiology of Aging, 2002, 23, S429.

151. Takao M, Piccardo P, Murrell J, Miravalle L, Vidal R, Brashear A, Farlow M, Unverzagt F, Connelally M, Foroud T, Glazier B, Ghetti B, Foster N, Towfighi J, Koto A, Hulette C, Cochran E. Neuropathologic heterogeneity associated with presenilin 1 gene mutations. Neurobiology of Aging, 2002, 23, S417.

152. Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA. PET and treatment response in Alzheimer’s disease. Neurobiology of Aging, 2002, 23(1S), S563.

153. Foster NL, Hong M, Shah GV, Adams KM, Turner RS. Reply to "Spontaneous intracranial hypotension causing reversible frontotemporal dementia". Neurology, 2002, 59, 787.

154. Foster NL. New opportunities to study real-world patient management [editorial]. Scandinavian Journal of Gastroenterology, 2003, 38, 341-342.

155. Foster NL, Koeppe RA, Rogers V, Minoshima S, Clark CM, Jagust WJ, Arnold SA, Barbas NR, DeCarli CS, Heidebrink JL, Turner RS. A multi-center trial to evaluate the clinical utility of FDG-PET. Neurobiology of Aging, 2004, 25, 246.

156. Foster NL, Nichols T, Koeppe RA, Giordani B, Kuhl D, Minoshima S, Lieberman A. The topographic progression of glucose hypometabolism in definite Alzheimer’s disease. Neurobiology of Aging, 2004, 25, S291-S292.

157. Heidebrink JL, Barbas NR, Turner RS, Clark CM, Jagust WJ, Arnold SE, DeCarli CS, Koeppe RA, Higdon R, Foster NL. FDG-PET improves differential diagnosis of dementia when clinical history and examination are ambiguous. Neurobiology of Aging, 2004, 25, S370-S371

158. Foster NL, Barbas NR, Heidebrink JL, Turner RS, Clark CM, Jagust WJ, Arnold SE, DeCarli CS, Koeppe RA, Higdon R. Adding FDG-PET to clinical information improves the accuracy of dementia diagnosis. Neurobiology of Aging, 2004, 25, S372.

159. Heidebrink JL, Arnold SE, Barbas NR, Clark CM, DeCarli CS, Jagust WJ, Turner RS, Higdon R, Koeppe RA, Foster NL. Diagnostic confidence in the clinical diagnosis of frontotemporal dementia and Alzheimer's disease. Annals of Neurology, 2004, 56(Suppl 8), S19.

160. Mordhorst MJ, Guidotti L, Langenecker SA, Caveney AK, Persad CC, Bieliauskas, Foster NL, Giordani B. Evidence of a Unique Contribution of Depression on Memory Function in a Clinical Sample. Journal of the International Neuropsychological Society. 2005, 11:19.

161. Foster NL, Plassman B, Langa K, Fisher GG, Giordani B, Wallace R. Factors influencing the frequency of dementia evaluations in a population-representative sample in the United States. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 2006, 2(Suppl 1), S262.

162. Foster NL, Koeppe RA, Heidebrink JL, Stevenson V, VanHuysen C for the Pilot Collaborative PET Imaging Trial. Quality assurance in a multi-center PET imaging trial. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 2006, 2(Suppl 1), S322.

163. Levy JA, Foster NL, Putnam KT, Seichepine DR, McGee L, Grimley M, Plumb T, Hammond CJ, Sunderland T. Altered semantic processing in healthy older adults at risk for Alzheimer’s disease. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 2006, 2(Suppl 1), S224.

PRESENTATIONSNorman L. Foster, M.D.

PROFESSIONAL PRESENTATIONS

International:

Sep 13, 2004 “Variation of the Phenotype in Frontotemporal Dementia”, Genotype-Proteotype-Phenotype Relationships in Neurodegenerative Diseases Hospital, Fondation Ipsen (Paris, France)

Sep 15, 2002 “Metabolic Correlates of Frontotemporal Dementia”, Frontotemporal Dementia/Pick’s Disease Conference, University of Western Ontario (London, Ontario, Canada)

Regional:

Nov 3, 2006 “Evaluation of Dementia and the Role of Neuropsychology”, Utah Psychological Association Annual Conference: Aging Research and Care in the 21st Century (SLC, UT)

Sep 23, 2006 “Brain Scanning as an Adjunct to Dementia Diagnosis” and panel member, “Brain Scanning in Dementia Diagnosis and Treatment: Research Tool, Clinical Adjunct or Both?”, 4th Annual Rocky Mountain Geriatric Conference (Deer Valley, UT)

Sep 22, 2006 Panel member, “Mild Cognitive Disorders: Definitions, Implications, To Treat or Not to Treat”, 4th Annual Rocky Mountain Geriatric Conference (Deer Valley, UT)

Sep 21, 2006 “Brain Scanning and Dementia”, 4th Annual Rocky Mountain Geriatric Conference (Deer Valley, UT)

Sep 20, 2006 “Dementing Diseases: At the Forefront of Neuroscience Research”, Brigham Young University Neuroscience and Physiology and Developmental Biology Seminar Series (Provo, UT)

Aug 30, 2006 “An Innovative Program for Dementia Care & Research”, Neurology/Neurosurgery Grand Rounds, University of Utah (SLC, UT)

Aug 22, 2006 “An Innovative Program for Dementia Care & Research”, University Neuropsychiatric Institute (UNI) Lunch Lecture (SLC, UT)

Aug 14, 2006 “Care for Alzheimer's Disease and Related Disorders in the 21st Century", ARUP Labs Lecture (SLC, UT)

Aug 1, 2006 “An Innovative Program for Dementia Care and Research", Geriatrics Grand Rounds, University of Utah (SLC, UT)

Jun 28, 2006 “Update on Dementia Care at the U of U”, Alzheimer’s Inpatient Service, Greenwood Clinic, University of Utah Hospitals and Clinics (Sandy, UT)

Jun 6, 2006 “Introduction to New U of U Alzheimer’s Program”, Salt Lake Senior Clinic, Salt Lake Regional Medical Center (SLC, UT)

Jun 6, 2006 Co-Presenter, “Primary Progressive Aphasia and Speech Disturbance in Dementia: Case Studies”, University of Utah Health Network (SLC, UT)

Apr 25, 2006 "Update on Alzheimer's Care", Grand Rounds, Logan Regional Hospital (Logan, UT)

Aug 20, 2005 “Recognizing and Treating Dementia in Psychiatric Patients”, Psychiatry Grand Rounds, University of Utah (Salt Lake City, UT)

Jul 7, 2004 “Variations in the Phenotype in Frontotemporal Dementia”, Neurology Grand Rounds, University of Michigan (Ann Arbor, MI)

Jan 20, 2004 “Recognizing Dementia in a Psychiatric Population”, Ann Arbor VAMC Psychiatry Grand Rounds

Jan 9, 2004 "Effective Strategies for Managing Dementia: Focusing on Patients and Families", Internal Medicine Grand Rounds, Oakwood Hospital (Dearborn, MI)

Oct 1, 2003 “How to Use Neuroimaging in the Evaluation of Dementia”, Neurology Grand Rounds, University of Utah (Salt Lake City, UT)

Jul 30, 2003 “How to Use Neuroimaging in the Evaluation of Dementia”, Neurology Grand Rounds, University of Michigan (Ann Arbor, MI)

Jul 23, 2003 "New Insights About Dementia from Molecular Imaging with PET", Neurology Grand Rounds, University of California at Irvine (Irvine, CA)

Apr 10, 2002 “Controversial Issues in Alzheimer’s Disease: Mild Cognitive Impairment – Panel Discussion”, Henry Ford Hospital (Detroit, MI).

Feb 15, 2002 “Treating Alzheimer’s Disease and Other Dementias”, Medical Staff Grand Rounds, Oakwood Hospital and Medical Center (Dearborn, MI)

Feb 11, 2002 “New Insights About Dementia from Molecular Imaging”, Neuroscience Grand Rounds, Cleveland Clinic Foundation (Cleveland, OH)

Jan 9, 2002 “Barriers to Treatment: The Unique Challenges for Physicians Providing Dementia Care”, Geriatrics Update, Genesys Regional Medical Center (Grand Blanc, MI)

Sep 28, 2001 “A 26-year old Man with Rapidly Progressive Dementia”, Discussant, Internal Medicine Grand Rounds Clinicopathological Conference, University of Michigan (Ann Arbor, MI)

Aug 29, 2001 “Can You Distinguish Alzheimer's Disease and Frontotemporal Dementia?: Clinical Case Presentations”, Neurology Grand Rounds, University of Michigan (Ann Arbor, MI)

Aug 17, 2001 “Practice Parameters: Should They Change Dementia Care?”, Michigan Alzheimer’s Disease Research Center Clinical Conference

Apr 30, 2001 “Remember Alzheimer’s Disease: We Can Help”, Medical Staff Rounds, Hackley Hospital (Muskegon, MI)

Apr 20, 2001 “What We Don’t Know About Alzheimer’s Disease and Why”, Michigan Alzheimer’s Disease Research Center Clinical Conference

Sep 6, 2000 “Use of Laboratory Markers for Diagnosis and Risk Assessment in Alzheimer's Disease”, Neurology Grand Rounds, University of Michigan (Ann Arbor, MI)

Feb 18, 2000 “Recent Findings and Future Research Directions for the Alzheimer’s Disease Cooperative Study”, Michigan Alzheimer’s Disease Research Center Clinical Conference

Feb 8, 2000 “Early Recognition and Initial Assessment of Dementia”, Division of General Medicine Rounds, University of Michigan (Ann Arbor, MI)

Oct 20, 1999 “Is it Dementia with Lewy Bodies or is it Alzheimer's Disease?”, Neurology Grand Rounds, University of Michigan (Ann Arbor, MI)

Nov 18, 1998 “Update on Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17” Neurology Grand Rounds, University of Michigan (Ann Arbor, MI)

Aug 24, 1988 “What We Have Learned About Dementia from Positron Emission Tomography”, Neurology Grand Rounds and Visiting Professor, University of Utah Medical Center (Salt Lake City, UT)

Jan 21, 1998 “Early Recognition and Initial Assessment of Dementia”, Family Medicine Grand Rounds, University of Michigan (Ann Arbor, MI)

Dec 5, 1997 “What We’ve Learned and What We Hope to Learn at the Michigan Alzheimer’s Disease Research Center”, Michigan Alzheimer's Disease Satellite Conference (Ann Arbor, MI)

Oct 29, 1997 “Dementia Care for African-Americans in Michigan: Can the Past Help Explain the Present?”, How the Past Affects the Future, The First Conference on Health Care Experiences of African Americans in Southeastern Michigan (Ann Arbor, MI)

Oct 8, 1997 “Why are the symptoms of AD so variable?”, Neurology Grand Rounds, University of Michigan (Ann Arbor, MI)

May 20, 1997 "Update on Alzheimer's Disease", Internal Medicine Grand Rounds, St. Mary's Hospital (Saginaw, MI)

May 19, 1997 "Alzheimer's Disease and Alzheimer's Mimics: What Autopsy Research is Telling Us", Solving the Puzzle of Dementia: Emerging Practice in Gerontology, 10th Annual Continuing Education Program on Issues in Aging sponsored by the Wayne State University Institute of Gerontology (Troy, MI)

Mar 5, 1997 "Early Identification of AD and Related Dementias", Department of Family Practice Grand Rounds, St. Luke's Hospital (Saginaw, MI)

Dec 12, 1996 "Dementia: Recognition, Assessment and Treatment", Medical Grand Rounds, Bay Medical Center (Bay City, MI)

Sep-Oct 1996 Continuing Medical Education Lecture Series, Northville State Psychiatric Hospital (Northville, MI)

Sept 25, 1996 “Update on Genetics in Alzheimer's Disease”

Oct 30, 1996 "Recognizing Atypical Dementia"

Dec 8, 1995 “Project 2: Neuropharmacological Challenges in Dementia, an Update”, Michigan Alzheimer’s Disease Research Center Investigators Meeting

Oct 4, 1995 “Alzheimer’s Disease: Diagnosis, Treatment, and Practical Appliciations of Research Advances”, Catherine McAuley Medical Center Grand Rounds (Ann Arbor, MI)

Sep 8, 1995 Family Practice Residents Conference, “Key Concepts for Dementia Diagnosis and Treatment,” and Physician Clinical Conference “Medical Management of Alzheimer’s Disease,” Marquette General Hospital (Marquette, MI)

Aug 12, 1995 “The Stubbed Toe Case (Familial CJD)”, Neurology Grand Rounds, University of Michigan (Ann Arbor, MI)

May 2, 1995 “Creutzfeldt-Jakob Disease”, Multi-Disciplinary Staff Conference, Flower Hospital (Toledo, OH)

Apr 17, 1995 “The Future of Alzheimer’s Disease: Research Enters Practice”, Medical Grand Rounds, Mid-Michigan Medical Center (Midland, MI)

Jan 25, 1995 “Dementia Care in the Age of Health Reform and Medical Malpractice”, Internal Medicine Update Conference, Oakwood Hospital (Dearborn, MI)

Sep 14, 1994 “Research Advances in Alzheimer’s Disease and Dementia”, Medical Staff Meeting, Marquette General Hospital (Marquette, MI)

Sep 13, 1994 “Research Advances in Alzheimer’s Disease”, Medical Staff Meeting, Bell Memorial Hospital (Ishpeming, MI)

Sep 7, 1994 “Progressive Limbic Lobe Sclerosis”, Neurology Grand Rounds, University of Michigan (Ann Arbor, MI)

Oct 29, 1993 “What’s New in Michigan About Alzheimer’s Disease”, Medical Staff Conference, Munson Medical Center (Traverse City, MI).

Oct 1993 Continuing Medical Education Lecture Series, Northville State Psychiatric Hospital (Northville, MI)

Oct 12, 1993 “Familial Risks for Alzheimer’s Disease”

Oct 27, 1993 “New Treatments for Alzheimer’s Disease”

May 14, 1993 “Meeting the Needs of Patients with Dementia and Their Families”, Internal Medicine Grand Rounds, McLaren Hospital (Flint, MI)

Apr 23, 1993 “Late-Breaking News About Alzheimer’s Disease”, Neurology Grand Rounds, Wayne State University (Detroit, MI)

Mar 30, 1993 “Physician Assessment of Dementia”, Assessment and Management of Older Adults with Dementia: A Focus on Ethnic Diversity, Geriatric Research, Education and Clinical Care Center (Ypsilanti, MI)

Nov 24, 1992 “The Role of PET in Diseases of the Brain”, Internal Medicine Grand Rounds, and “The Application of PET”, Combined Neurology/Neurosurgery/Radiology Grand Rounds, Southern Illinois University School of Medicine (Springfield, IL)

March 12, 1993 “Recognition and Diagnosis of Atypical Dementias”, Alpena General Hospital Staff Meeting (Alpena, MI)

Dec 9, 1992 “PET Imaging in Dementia - Is It Really Worthwhile?”, Neurology Grand Rounds, University of Michigan (Ann Arbor, MI)

Nov 4-5, 1992 “Clinical Utility of PET in Evaluating Dementia” and “PET and the Neurobiology of Alzheimer’s Disease”, Neurology and Nuclear Medicine Grand Rounds, State University of New York at Buffalo

Oct 7, 1992 “Meeting the Needs of Patients with Alzheimer’s Disease and Their Families”, Guest Lecture Series, Flint Osteopathic Hospital (Flint, MI)

Jun 17, 1992 “Issues in Dementia Relevant to Care in Psychiatric Hospitals”, Continuing Medical Education Lecture Series, Walter P. Reuther Psychiatric Facility (Westland, MI)

Mar 11, 1992 “Developing Effective Therapies for Alzheimer’s Disease: The Potential Role of PET”, Neurology Grand Rounds, University of Michigan (Ann Arbor, MI)

Jan 9-10, 1991 “Differential Diagnosis of Dementia and “Cognitive Management”, Clair Martig Alzheimer’s Disease Symposium, Medical College of Ohio (Toledo, OH)

Oct – Nov 1990 Continuing Medical Education Lecture Series, Northville State Psychiatric Hospital

Oct 4, 1990 “The Differential Diagnosis of Dementia”

Nov 1, 1990“The Role of Amyloid and Endogenous Neurotoxins”

Sep 5, 1990 “Frontal Lobe Degeneration of the Non-Alzheimer Type”, Neurology Grand Rounds, University of Michigan (Ann Arbor, MI)

Mar 23, 1990 “Dementia and Delirium in the Elderly”, Intensive Course in Geriatrics and Geriatrics Board Review, sponsored by Catherine McAuley Health Center (Ann Arbor, MI)

Mar 3, 1990 “SPECT Imaging in the Diagnosis of Dementia -- A Neurologist’s Perspective”, Michigan College of Nuclear Medicine Physicians, Beaumont Hospital (Royal Oak, MI)

Jan 24, 1990 “Glutamate and Alzheimer’s Disease: Neuropharmacological Challenges with Ketamine”, Neurology Grand Rounds, University of Michigan (Ann Arbor, MI)

Jan – Feb 1989 Continuing Medical Education Lecture Series, Ypsilanti State Psychiatric Hospital (Ypsilanti, MI)

Jan 13, 1989 “Clinical Features of Alzheimer’s Disease and Related Disorders”

Jan 27, 1989 “Recent Advances in Our Understanding of Alzheimer’s Disease”

Feb 10, 1989 “Brain Imaging in Dementia”

Aug – Sep 1988 Continuing Medical Education Lecture Series, Northville State Psychiatric Hospital (Northville, MI)

Aug 3, 1988 “Clinical Features of Alzheimer’s Disease and Related Disorders”

Sep 7, 1988 “Recent Advances in Our Understanding of Alzheimer’s Disease”

Sep 28, 1988 “Brain Imaging in Dementia”

Nov 18, 1987 “Sensory Neuropathy”, Neurology Grand Rounds, University of Michigan (Ann Arbor, MI)

May 18, 1987 “PET in Normal Aging, ‘Subcortical’ and ‘Cortical’ Dementia”, Neurology Grand Rounds, Case Western Reserve University (Cleveland, OH)

Nov 7, 1986 “Alzheimer’s Disease. An Overview: Symptomatology, Diagnosis, Assessment and Research Trends”, Alzheimer’s Disease: Current Issues in Diagnosis and Management, Ypsilanti Regional Psychiatric Hospital, sponsored by the Michigan Department of Mental Health (Ypsilanti, MI)

Jun 13, 1986 “PET studies in Alzheimer’s Disease”, Neurology Grand Rounds, Henry Ford Hospital (Detroit, MI)

Jun 27, 1986 “New Concepts of Dementia”, Neurology Grand Rounds, Wayne State University School of Medicine (Detroit, MI)

Jun 6, 1986 “Cognitive Defects in Alzheimer’s Disease”, Michigan Association for Neuropsychiatric Hospitals and Clinics, Physician’s Spring Meeting, Northville State Hospital (Northville, MI)

Jun 4, 1986 “PET Studies of Progressive Supranuclear Palsy”, Neurology Grand Rounds, University of Michigan (Ann Arbor, MI)

Dec 4, 1985 “Recent Advances in Alzheimer’s Disease”, Internal Medicine Grand Rounds, Beaumont Hospital (Royal Oak, MI)

Mar 20, 1985 “Neurological Complications of Acquired Immune Deficiency Syndrome (AIDS)”, Neurology Grand Rounds, University of Michigan (Ann Arbor, MI)

LECTURES PRESENTED AT SCIENTIFIC MEETINGS

International:

Apr 11-13, 2006 Lecture: “Dementia, Diagnosis and Management”, and special interest group discussion leader: “Dementia”, The 1st Annual King Faisal Hospital & Research Centre Geriatrics Symposium (Riyadh, Saudi Arabia)

Feb 18, 1984 “Peripheral Beta-Adrenergic Blockade Treatment of Parkinsonism Tremor”, The Increasing Clinical Value of Beta-Blockers -- An International Symposium (Casa de Campo, Dominican Republic)

National:

Nov 11-12, 2005 General Electric Healthcare (GEHC) PET Investigator Network, Investigator Meeting (Princeton, NJ)

Dec 13-14, 2005 “Value and Feasibility of Neuroimaging in the HRS/ADAMS”, Aging, Demographics, and Memory Study (ADAMS) II Planning Conference (Ann Arbor, MI)

Nov 2, 2005 “The Role of Neuroimaging in the Evaluation of Dementia”, 6th Annual Norman N. Krieger, M.D. Lecture in Geriatric Medicine (Novi, MI)

Jul 18-20, 2005 “Imaging and Alzheimer’s Disease”, Cache County Study on Memory, Health & Aging: CCMS & DPS Initiatives (Logan, UT)

Jun 10-12, 2005 Flurizan National Advisory Board Meeting, Grand America Hotel and Myriad Genetics, Inc. (SLC, UT)

Sep 8-9, 2004 Panelist, “Discussion of Neuroimaging and Biomarkers”, Mild Cognitive Impairment (MCI): Alzheimer’s Association Research Roundtable, Marriott Wardman Park Hotel (Washington, DC)

Apr 5, 2004 “PET in Differential Diagnosis of Select Cases of Dementia”, Neuroimaging in the Diagnosis of Alzheimer’s Disease and Dementia (Bethesda, MD)

Mar 5, 2004 “The Role of Neuroimaging in the Diagnosis of Alzheimer’s Disease”, Alzheimer’s Disease Update 2004: National Conference on the Practical Management of Alzheimer’s Disease (Tulsa, OK)

Feb 26, 2004 “Biomarkers for Use in Early Diagnosis and as Surrogate Outcome Measures for Neuroprotective Trials: Neurodegenerative Disease”, Thomas N. Chase, MD Symposium - A Tribute to his Research at NIH, National Institutes of Health (Bethesda, MD)

Nov 5, 2003 “Research Advances and New Treatment Options for Alzheimer’s Disease”, the 4th Annual Norman N. Krieger Lecture in Geriatric Medicine (Novi, MI)

Apr 4, 2003 “How to Use Neuroimaging in the Evaluation of Dementia”, Dementia Update Course, Claudia Kawas, Course Director, 55th Annual Meeting, American Academy of Neurology (Honolulu, HI)

Apr 3, 2003 “Scientific Topic Highlights: Dementia/Behavioral Neurology”, 55th Annual Meeting, American Academy of Neurology (Honolulu, HI)

Jun 18, 2002 “A Multi-center Study to Validate FDG-PET as a Diagnostic Biomarker for Dementia”, Alzheimer’s Disease Neuroimaging Initiative, National Institute on Aging (Bethesda, MD)

Nov 7, 2001 "Isolated Memory Impairment: Exploring the Borderlands of Dementia", 2nd Annual Norman N. Krieger, MD Lectureship in Geriatric Medicine, Huron Valley-Sinai Hospital, Novi Hilton (Novi, MI)

Oct 19, 2000 "Progress in Understanding and Effectively Treating Alzheimer's Disease", 1st Annual Norman N. Krieger, MD Lectureship in Geriatric Medicine, Huron Valley-Sinai Hospital, Townsend Hotel (Birmingham, MI)

Jul 26, 2000 “Use of Laboratory Markers for Diagnosis and Risk Assessment in Alzheimer’s Disease”, Edutrack Program 3403, Advances in the Pathogenesis and Diagnosis of neurodegenerative Diseases, Anthony A. Killeen, MD, Ph.D., moderator, 52nd Annual Meeting of the American Association for Clinical Chemistry (San Francisco, CA). Proceedings Published: Clin Chem 2000; 46: S32

Apr 30, 2000 “Dilemmas in Diagnostic Classification for Dementia Research: Frontotemporal Dementias”, Alzheimer Disease Center Clinical Core Director’s Meeting (San Diego, CA)

Sep 16, 1999 “PET Measures of Glucose Metabolism and Cholinergic Function in Alzheimer’s Disease” and “Assessment of Cholinesterase Inhibitors with PET”, Alzheimer’s Disease Symposium, Arena Pharmaceuticals (San Diego, CA)

May 25, 1999 “Does Mild Cognitive Impairment (MCI) Progress to Non-Alzheimer Dementia”, Current Concepts of Mild Cognitive Impairment (Chicago, IL)

Oct 18, 1987 “Dementias of the Movement Disorders: PET and Clinical Studies”, 7th Annual Meeting of the American Society for Neurological Investigation (San Francisco, CA)

Oct 21, 1982 “New Brain Imaging Techniques: Positron Emission Tomography and Nuclear Magnetic Resonance”, 13th Annual Meeting, American Academy of Psychiatry and the Law (NY)

Regional:

Nov 3, 2006 “Evaluation of Dementia and the Role of Neuropsychology”, Utah Psychological Association Annual Meeting (Salt Lake City, UT)

Oct 7-8, 2005 “Alzheimer's Disease Update: Diagnosis and Treatment" and "The Use of PET in Neurological Disease”, Western Intermountain Neurological Organization Fall Meeting (Salt Lake City, UT)

Jun 25, 2004 “Contributions of PET Imaging to AD Assessment”, Alzheimer’s Disease: Translating Research into Practice, Inaugural Regional CME Meeting Sponsored by the Education Cores of the Six Midwest NIA-funded Alzheimer’s Disease Centers (Indianapolis, IN)

Jun 12, 2004 "Research Advances and New Treatment Options for Dementing Diseases", Michigan Neurological Association Annual CME Meeting, Grand Traverse Conference Center (Acme, MI)

Jul 22, 2003 “Evaluation and Treatment of Dementia”, Orange County Neurological Society (Costa Mesa, CA)

May 2, 2003 “Using PET in Clinical Drug Development for Alzheimer’s Disease”, Facilitating the Development of PET Diagnostics for Alzheimer’s Disease Catalyst Conference, New York Academy of Sciences (New York, NY)

Mar 8, 2003 “Validating FDG-PET as a Biomarker for Frontotemporal Dementia”, Advancing the Science of Neurologic Diseases: A Tribute to Sid Gilman (Ann Arbor, MI)

Nov 7, 2002 "The Challenge of Prion Diseases in Michigan: Underrecognized or Impending Epidemic?" Keynote Speaker, Michigan Infectious Disease Society and Michigan Department of Community Health Annual Scientific Conference, Botsford Hospital (Farmington, MI)

Oct 8, 2002 “Creutzfeldt-Jakob Disease in Michigan”, Michigan Dementia Coalition, Quarterly Meeting (Howell, MI)

Dec 1, 2001 “Addressing Common Issues in Dementia Care: Driving”, Dementia in Primary Care: Physicians Leading the Way, sponsored by the Michigan Dementia Coalition and the Michigan State Medical Society Committee on Aging, Ashman Court Hotel (Midland, MI)

Feb 26, 1999 “Participation of African Americans in Health Care Systems”, and “Strategies for Learning More About Disease in African Americans”, African-American Health Care Experiences in Southeast Michigan: How the Past Shapes Today and Tomorrow (Detroit, MI)

Aug 14, 1998 "Recognition and Treatment of Dementia", US-Japan Training Institute in Geriatric Care (Ann Arbor, MI)

Aug 12, 1997 "Recognition and Treatment of Dementia", US-Japan Training Institute in Geriatric Care (Ann Arbor, MI)

Aug 20, 1996 "Recognition and Treatment of Dementia", US-Japan Training Institute in Geriatric Care (Ann Arbor, MI)

Nov 2, 1995 “Alzheimer’s Disease: An Update on Treatment and Research Advances”, 130th Annual Scientific Meeting, Michigan State Medical Society (Lansing, MI)

Aug 14, 1995 Focus on Dementia, US-Japan Training Institute in Geriatric Care

Apr 28, 1995 “The Genetics of Alzheimer’s Disease”, Annual Training for Community Mental Health and Department of Mental Health Dementia Staff (Gaylord, MI)

Apr 18, 1995 “Update on Alzheimer’s Disease”, Gladwin County Medical Society (Gladwin, MI)

Jan 25, 1995 “Dementia and Alzheimer’s Disease in African-Americans in Michigan”, Detroit Medical Society (Detroit, MI)

Oct 22, 1994 “New Frontiers in Alzheimer’s Disease Treatment and Research”, Physician’s Forum on Alzheimer’s Disease (Alpena, MI)

Oct 20-21, 1994 “Overview of Alzheimer’s Disease” and “New Frontiers in Alzheimer’s Disease”, Alzheimer’s Awareness Conference (Alpena, MI)

Sep 22, 1994 “Hope for the future: Latest Advances in Management and Treatment”, 1st Annual Conference, Northwest Michigan Alzheimer’s Services Coordinating Committee, Sugarloaf Resort (Maple City, MI)

Sep 15, 1994 “New Frontiers in Alzheimer’s Disease”, Alzheimer Information and Dementia Education Conference (Marquette, MI)

Aug 11, 1994 Focus on Dementia, US-Japan Training Institute in Geriatric Care (Ann Arbor, MI)

Apr 21, 1994 “Alzheimer’s Disease: An Update on Treatment and Research Advances”, Annual Training for Community Mental Health and Department of Mental Health Dementia Staff (Gaylord, MI)

Nov 9, 1993 Course Director and Speaker: “What’s New About Alzheimer’s Disease in Michigan“, Annual Scientific Meeting, Michigan State Medical Society (Detroit, MI)

Oct 12, 1993 “Meeting the Needs of Patients with Dementia and Their Families”, Sanilac County Medical County (Sandusky, MI)

Aug 19, 1993 Focus on Dementia, US-Japan Training Institute in Geriatric Care (Ann Arbor, MI)

Jul 7, 1993 “Ketamine Challenges in Alzheimer’s Disease and Normal Aging”, Visiting Lecture Series, Parke-Davis Pharmaceutical Research Division (Ann Arbor, MI)

Nov 17, 1992 Course director and speaker: “What’s New About Alzheimer’s Disease in Michigan“, Annual Scientific Meeting, Michigan State Medical Society (Dearborn, MI)

Sep 16, 1992 “CT and MRI in the Diagnosis of Dementia”, Third Annual All Ohio Alzheimer’s Disease Symposium (Toledo, OH)

Sep 16, 1992 “CT and MRI in the Diagnosis of Dementia”, All-Ohio Alzheimer’s Disease Symposium (Toledo, OH)

Aug 18, 1992 “Focus on Dementia”, U.S.-Japan Training Institute in Geriatric Care (Ann Arbor, MI)

May 7, 1991 “Assessment and Management of Dementia” conference sponsored by Michigan Alzheimer’s Disease Research Center, Geriatric Center and Veteran’s Administration Regional Educational Center (Ann Arbor, MI)

Apr 26, 1991 Course instructor: “Dementia: Neurobiology Update, Differential Diagnosis and Management” and presenter: “Use of Brain Imaging in Diagnosis and Management of Dementia”, 3rd Annual Meeting Academy of Neurology (Boston, MA)

EDUCATIONAL LECTURES

Regional:

Oct 6-7, 2005 Critical Clinical Issues in the Care of the Older Adult: Pain Management and Palliative Care Meeting, University of Michigan Medical School (Ann Arbor, MI)

Aug 4, 2004 “Opportunities and Challenges of Neuroimaging Research in Dementing Diseases”, Sanders Brown Center on Aging, University of Kentucky (Lexington, KY)

Apr 18, 2000 “Alzheimer’s Disease: Diagnostic Approach and Differential Diagnosis”. Novartis Alzheimer’s Disease Preceptorship, sponsored by the University of Michigan College of Pharmacy (Ypsilanti, MI)

Apr 18, 2000 “Alzheimer’s Disease: Diagnostic Approach and Differential Diagnosis”, Novartis Alzheimer’s Disease Preceptorship, sponsored by the University of Michigan College of Pharmacy (Ypsilanti, MI)

May 19, 1998 "What's New in AD Research", "Diseases that Mimic Alzheimer's Disease", and "Diagnosis and Treatment of Alzheimer's Disease", Alzheimer's Disease: Walking the Path Together, the Third Dr. Richard Seyfarth Schreiber Memorial Seminar, Western Michigan University (Kalamazoo, MI)

University of Utah:

Nov 20, 2006 “The Aging Brain”, Interdisciplinary Seminar Series on Aging, College of Social Work

Nov 15, 2006 “An Innovative Program for Dementia Care”, University of Utah Communications Council (SLC, UT)

Oct 18, 2006 “Dementia and Cognitive Testing”, Clinical Neurosciences Core IV Lecture, Department of Neurology

Oct 4, 2006 “The Gift to Life Program”, Neurology Lecture

Oct 4, 2006 “What We Learned at FasterCures and the International FTD Conference”, CACIR faculty and staff meeting

Aug 30, 2006 “The Recognition and Initial Assessment of Dementia”, WATS Family Medicine Lecture

Aug 15, 2006 “What We Learned at the 10th Annual International Conference on Alzheimer’s Disease (ICAD) in Madrid”, CACIR and Neurology faculty and staff

2005 - 2006 Visiting Professor Symposia Series, The Brain Institute

Nov 2, 2006: David Darby, MD

Sep 27, 2006: Garrett Riggs, MD

Jun 29, 2006: "Geriatric Neuropsychological Intervention: An Evolving Practice Landscape", Deborah Koltai-Attix, PhD, Duke University

2005 – 2006 Neuroimaging Symposia Series, The Brain Institute

Oct 25, 2006: Small Animal Imaging

Jan 30, 2006: Moderator, “Are There Two Distinct Forms of Lewy Body Disease? Lessons from a Community-Based Study” by James B. Leverenz, Associate Professor of Neurology, Psychiatry and Behavioral Sciences at the University of Washington.

Jan 25, 2006: Overview and Presenter, “Neuroimaging at Utah: Image Acquisition.” Presenter, “What the Alzheimer’s Disease Neuroimaging Initiative (ADNI) means for Researchers.” Co-presenter: John M. Hoffman, MD.

Nov 30, 2005: Overview and Moderator, “Neuroimaging at Utah: Strategies for Collaboration.”

Oct 27, 2005: Overview and Moderator, “Neuroimaging at Utah.” Presentations by Gordon Chelune, PhD (“Defining reliable change in cognition at the level of the individual: The problem of longitudinal assessment of elderly individuals”) and James Levy, PhD (“Subtle Cognitive Effects Associated with Genetic Risk for Alzheimer’s Disease”).

2005 – 2006 Presenter, Clinical Neurology Conferences, School of Medicine

May 24, 2006: “Autopsy and Dementia”

Apr 19, 2006: “Neuroimaging in Dementia”

Mar 29, 2006: “Prion Disease”

Mar 24, 2006: “Drug Treatment of Dementia”

Feb 8, 2006: “Non-pharmacological Treatment of Dementia”

Feb 1, 2006: “Clinical Research in Dementia”

Jan 25, 2006: “Vascular Dementia”

Jan 4, 2006: “Genetics and Pathophysiology of Dementia”

Nov 16, 2005: “Differential Diagnosis of Dementia”

Nov 9, 2005: “Recognition and Initial Assessment of Dementia”

Sep 21, 2005: “Introduction to Dementia”

Aug 21, 2005: “An Introduction to New Dementia Programs and Research at the

University of Utah”

Feb 11, 2004 "Opportunities and Challenges for Neuroimaging Research of Dementing Diseases", Radiology Research Seminar, University of Utah (Salt Lake City, UT)

University of Michigan:

Feb 16, 2005 “Imaging in Dementia”, Neuroradiology Faculty and Fellows Conference (1.5 hours, 10 faculty and fellows)

Feb 3, 2005 “Opportunities and Challenges for Neuroimaging Research in Dementing Diseases”, Institute of Gerontology 2004-2005 Seminar Series

Nov 18, 2004 “Dementia and MCI – Evidence Based Treatment, Neurology Thursday Noon Conference

Nov 16, 2004 “Dementias: Epidemiology, Clinical Assessment, and Treatments”, Epidemiology 677 – Epidemiology of Aging (Mary Haan, course director), School of Public Health (3 hours, 18 students)

Nov 11, 2004 “Dementia and MCI – Diagnosis, Testing, and Driving Issues, Neurology Thursday Noon Conference

Oct 27, 2004 “Visual Variant of Alzheimer’s Disease”, Neurology Clinical Case Conference

Jun 30, 2004 “Frontotemporal dementia, dementia with Lewy bodies, and Mild Cognitive Impairment”, Noon Geriatric Social Work Conference (25 attendees)

Mar 31, 2004 “Recognizing Dementia in Orthopedic Patients”, Orthopedics Adult Reconstruction Conference

Mar 17, 2004 “Introduction to Dementia”, Reynolds Foundation Program for Lead Faculty

Mar 11, 2004 “Recognizing Dementia in Physical Medicine and Rehabilitation Patients,” Physical Medicine and Rehabilitation Resident Conference Series

Mar 4, 2004 “Autopsy in Neurology: Procedure, Benefits, Limitations, and Consents”, Neurology Thursday Noon Conference

Dec 9, 2003 “Drug Treatment of Dementia”, Nursing N505 Bio-Behavior (for Advanced Training Nursing Students), Laura Struble, Ph.D., course director

Nov 18, 2003 “How to Use Neuroimaging in the Evaluation of Dementia”, Geriatric Clinical Noon Conference

Nov 4, 2003 “Early Recognition, Diagnosis, and Treatment of Dementia”, General Medicine Conference, East Ann Arbor Health Center

Oct 10, 2003 “Looking at Alzheimer's Disease in 4 Dimensions”, Neuropsychology Division Journal Club

Oct 30, 2003 “Creutzfeldt-Jakob Disease and Whipple’s Disease: Two Cryptic Infectious Causes of Dementia”, Neurology Thursday Noon Conference

Sep 18, 2003 Guest Rounder in Geriatrics, University of Michigan Inpatient Gastroenterology Service with Laurel Fisher (supported by the Donald W. Reynolds Foundation Comprehensive Programs to Strengthen Physicians’ Training in Geriatrics)

Mar 10, 2003 “Dementia”, Neuroscience Sequence, Component II (Constance J. D’Amato and Rachel Glick, sequence directors) (2 hours)

Apr 24, 2003 “Scientific Highlights in Dementia and Aging from the 55th Annual Meeting of the American Academy of Neurology”, Neurology Thursday Noon Conference

May 30, 2003 Geriatric Faculty and Fellows Journal Club, with Asif Ishaque and Adnan Beg, Memantine Trial and Postmortem Evaluation of Patient Receiving Immunotherapy for Alzheimer’s Disease

Dec 13, 2002 “Update on CJD, Chronic Wasting Disease and the Vaccine for Alzheimer’s Disease”, Neurology Professional Secretarial Support Team meeting

Series: “Overview of Dementia”, Collaborative Intraprofessional Team Education Program Trainees (1 hour, physician, social work, pharmacy and nursing trainees)

January 15, 2003

February 19, 2003

March 12, 2003

May 14, 2003

Dec 5, 2002 “What to Expect and Surprises in the Cognitive Disorders Clinic”, Neurology Thursday Noon Clinical Conference

Nov 25, 2002 “Introduction to Dementia”, Reynolds Foundation Program for Lead Faculty

Mar 11, 2002 “Dementia”, Neuroscience Sequence, Component II (Constance J. D’Amato and Rachel Glick, sequence directors) (2 hours)

May 31, 2002 “Hormone Replacement Therapy and Alzheimer’s Disease”, Neurology Professional Secretarial Support Team meeting (with Rudy Ansbacher, MD)

Feb 15, 2002 “Are Current AHCPR Guidelines for the Recognition and Initial Assessment of Dementia Valid?”, Michigan Alzheimer’s Disease Clinical Conference

Jan 3, 2002 “Creutzfeldt-Jakob Precautions in the Operating Room and Two Recent Cases”, Thursday Morning Operating Room Staff Meeting (70 attendees)

2002 Series: “Overview of Dementia”, Collaborative Intraprofessional Team Education Program Trainees (1 hour, physician, social work, pharmacy and nursing trainees)

January 16, 2002

February 13, 2002

March 13, 2002

May 8, 2002

June 12, 2002

September 11, 2002

October 9, 2002

November 13, 2002

December 11, 2002

2001 Series: “Dementia”, Collaborative Intraprofessional Team Education Program Trainees (2 hours, physician, social work, pharmacy and nursing trainees)

March 28, 2001

April 18, 2001

May 30, 2001

September 12, 2001

October 10, 2001

November 14, 2001

Dec 6, 2001 “Introduction to the Cognitive Disorders Clinic”, Neurology Thursday Noon Conference

Nov 8, 2001 “The Neurological Examination”, Introduction to the Patient, Clinical Skills Laboratory (six M-1 students, 2 hours)

Nov 21, 2001 “Dementia Care for the Primary Care Physician”, Family Medicine Lecture Series (15 residents and medical students, 2 hours)

Aug 21, 2001 “Introduction to the Cognitive Disorders Clinic”, Geriatric Medicine Tuesday Noon Clinical Conference

Apr 18, 2001 “Understanding Alzheimer’s Disease and Other Dementia to Improve Care”, Hartford Geriatric Integrative Seminar, University of Michigan School of Social Work, (2 hours, 15 students, Ruth Dunkle, Ph.D., instructor and Principal Investigator, Hartford Geriatric Fellowship

Mar 12, 2001 “Dementia”, Neuroscience Sequence, Component II (Constance J. D’Amato and Rachel Glick, sequence directors) (2 hours)

Oct 5, 2000 “Autopsy”, Neurology Thursday Clinical Conference

Aug 18, 2000 “Clinical and Ethical Considerations for Genetic Testing in Neurodegenerative Disease” Discussant, Michigan Alzheimer’s Disease Research Center Clinical Conference

Jul 21, 2000 “Hot Topics and Trends from the 2000 World Alzheimer Congress”, Michigan Alzheimer’s Disease Research Center Clinical Conference

May 15, 2000 “Mild Cognitive Impairment”, Health and Retirement Survey Seminar Series

Mar 8, 2000 “Dementia”, Neuroscience Sequence, Component II (Constance J. D’Amato and Rachel Glick, sequence directors) (2 hours)

Feb 2, 2000 “Recent Experience with Rapidly Progressive Dementia: Clinical, CSF and Pathological Correlations” (with Mila Blaivas), Neurology Thursday Noon Clinical Conference

Feb 16, 2000 “Aphasia and Apraxia”, Neuroscience Sequence, Component II (Constance J. D’Amato and Rachel Glick, sequence directors) (1 hour)

Jan 28, 2000 “Creutzfeldt-Jakob Disease”, Neurology Academic Secretaries and Clinic Support Staff meeting

Jan 14, 2000 “A Tour and Overview of the Cognitive Disorders Clinic”, Site Visit, Societal Analysis of Aging (HMP 673), School of Public Health, Jersey Liang, Ph.D., instructor

2000 Series: “Dementia”, Interdisciplinary Conference for Innovations in Health Professions Education Trainees (2 hours, physician, social work, pharmacy and nursing trainees)

January 19, 2000

February 16, 2000

March 22, 2000

April 19, 2000

September 20, 2000

Dec 7, 1999 Organizer and Moderator, “Workshop on Dementia Training for Primary Care Physicians”

Nov 12, 1999 “Neurology Videos – Movement and Cognitive Disorders”, Neurology Academic Secretaries and Clinic Support Staff meeting

Nov 23, 1999 Organizer and Moderator, “Neuropsychological Assessment of Dementia”, Michigan Union

Aug 10, 1999 “Early Recognition and Initial Assessment of Dementia”, Geriatric Medicine Noon Clinical Conference

Aug 26, 1999 “Introduction to Cognitive Disorders Clinic”, Neurology Resident Monday Noon Lecture Series

1999 Series: “Dementia”, Interdisciplinary Conference for Innovations in Health Professions Education Trainees (2 hours, physician, social work, pharmacy and nursing trainees)

January 25, 1999

February 17, 1999

March 24, 1999

May 19, 1999

August 18, 1999

September 8, 1999

October 20, 1999

November 10, 1999

December 15, 1999

Mar 5, 1999 “Progressive Supranuclear Palsy”, Geriatric Dentistry Seminar

Mar 10, 1999 “Dementia”, Neuroscience Sequence, Component II (Constance J. D’Amato and Rachel Glick, sequence directors) (2 hours)

Mar 15, 1999 “Consensus Clinical Criteria have Limited Ability to Distinguish Dementia with Lewy Bodies and Alzheimer’s Disease”, and Discussant on “Does the Entorhinal Pathology Explain the Discordance between Glucose Metabolic and Pathologic Changes in Very Early Alzheimer's Disease?, Nuclear Medicine Conference

Jan 14, 1999 “Creutzfeldt-Jakob Disease”, Neurology Resident Thursday Noon Clinical Conference

Jan 25, 1999 “Physiologic and Structural Discrepancies in AD with PET”, Discussant, Nuclear Medicine Conference

Jan 19, 1998 Commentator on “PET in the diagnosis of dementia” by Satoshi Minoshima, Nuclear Medicine Controversy Conference

Feb 12, 1998 “Update on Dementia”, University of Michigan Health Service Conference

Mar 11, 1998 “Dementia”, Neuroscience Sequence, Component II (Constance J. D’Amato and Rachel Glick, sequence directors) (2 hours)

Mar 19, 1998 “The Neurological Examination”, Introduction to the Patient, Clinical Skills Laboratory, (Andrew J. Zweifler, M.D., course director)

Apr 4, 1998 “Introduction to Dementia”, Neurology for Psychiatry Residents Day, Novi Hilton

Aug 18, 1998 “Introduction to Cognitive Disorders Clinic”, Neurology Resident Monday Noon Lecture Series

Aug 25, 1998 “Early Identification and Initial Assessment of Dementia”, Geriatrics Tuesday Noon Clinical Conference

1998 Series: “Dementia”, Interdisciplinary Conference for Innovations in Health Professions Education Trainees (2 hours, physician, social work, pharmacy and nursing trainees)

August 26, 1998

September 30, 1998

October 28, 1998

December 23, 1998

Dec 9, 1998 “Ethical Issues Related to Biodemographic Research on the Elderly”, Panel Discussion, University of Michigan Population Studies Center

Feb 18, 1997 Treatment of Alzheimer's Disease", Clinical Pharmacology & Therapeutics (PHMRX-D.101U), Ed Domino, M.D., course director

Mar 12, 1997 “Dementia”, Neuroscience Sequence, Component II (Constance J. D’Amato and Rachel Glick, sequence directors) (2 hours)

Mar 18, 1997 “Isolated Memory Impairment", Geriatrics Tuesday Noon Clinical Conference

Mar 18, 1997 “The Neurological Examination", Introduction to the Patient, Clinical Skills Laboratory, (Andrew J. Zweifler, M.D., course director)

Apr 22, 1997 “A Proposed Study of Sleep in Alzheimer's Disease”, Tuesday Sleep Conference

Jun 26, 1997 “Alzheimer's Disease - What is the Physician's Role”, Josiah Macy Jr. Foundation Minorities in Medicine Summer Science Academy

Aug 21, 1997 “Introduction to Cognitive Disorders Clinic”, Neurology Resident Monday Noon Lecture Series (repeated September 29, 1997)

Oct 17, 1997 “Early Recognition and Treatment of Alzheimer's Disease”, Friday Noon Conference Hospital Dental Service

Nov 13, 1997 “Isolated Memory Impairment”, Neurology Resident Thursday Noon Clinical Conference

Aug 26, 1996 “Introduction to Cognitive Disorders Clinic”, Neurology Resident Monday Noon Lecture Series

Oct 22, 1996 “Genetics In Alzheimer’s Disease”, Geriatrics Thursday Noon Clinical Conference

Feb 1, 1995 “Applying Neuroscience Principles to Understanding AD”, Nursing Research Conference

Feb 21, 1995 “Neurology and Psychiatry Overlap Case Discussions”, Neuroscience Sequence, Component II (Constance J. D’Amato and Rachel Glick, sequence directors) (3 hours)

Mar 3, 1995 “Treatment of Dementia”, Clinical Pharmacology and Therapeutics PHMRX-D.101.U (E. F. Domino, course director)

Mar 8, 1995 “Dementia I and II”, Neuroscience Sequence, Component II (Constance J. D’Amato and Rachel Glick, sequence directors) (2 hours)

Mar 13, 1995 “Aging of the Brain: Dementia of The Alzheimer Type”, Chapter 62, Kandel, Monday noon Neuroscience Conference

Mar 31, 1995 “The Use of Tacrine in Alzheimer’s Disease”, Internal Medicine Noon Conference

Aug 31, 1995 “Introduction to Cognitive Disorders”, Neurology Noon Clinical Conference

Sep 12, 1995 “Recognizing Atypical Dementia”, Geriatrics Noon Clinical Conference

Nov 29, 1995 “Dementia”, Family Practice Residents Conference

Feb 9, 1994 “Headache” Neuroscience Sequence, Component II (Constance J. D’Amato and Rachel Glick, sequence directors) (2 hours)

Feb 16, 1994 “Dementia” Neuroscience Sequence, Component II (Constance J. D’Amato and Rachel Glick, sequence directors) (4 hours)

Feb 18, 1994 “Multidisciplinary Conference on Dementia” Neuroscience Sequence, Component II (Constance J. D’Amato and Rachel Glick, sequence directors) (2 hours)

Aug 11, 1994 “Current Theories on the Pathogenesis of Alzheimer’s Disease”, Hartford Foundation Student Fellowship Seminar

Aug 16, 1994 `“Neurological and Cognitive Assessment”, Division of Geriatric Medicine Clinical Conference

Aug 18, 1994 “Introduction to Cognitive Disorders”, Neurology Noon Clinical Conference

Oct 11, 1994 “Autopsy and Legal Issues in Dementia”, Division of Geriatric Medicine Clinical Conference

Mar 16, 1993 “Pathophysiology of Headache”, Neural and Behavioral Sciences 600 (Constance J. D’Amato, Course Director) (2 hours)

Apr 13, 1993 “Dementia”, Neural and Behavioral Sciences 600 (Constance J. D’Amato, Course Director) (2 hours)

Dec 9, 1993 “PSP: A Preventative Medicine Approach”, Neurology Noon Clinical Case Conference

Dec 13, 1993 “Synaptic Transmission Mediated by Second Messengers”, Neurology Neuroscience Conference

Jan 10, 1992 “Plans for Competing Renewal of the Clinical Core”, ADRC Investigators Meeting

Feb 10, 1992 “FDG and Idebenone”, Nuclear Medicine Research Conference

Mar 17, 1992 “Pathophysiology of Headache”, Neural and Behavioral Sciences 600 (Constance J. D’Amato, Course Director) (2 hours)

Apr 21, 1992 “Dementia”, Neural and Behavioral Sciences 600 (Constance J. D’Amato, Course Director) (2 hours)

Oct 15, 1992 “Dementia in PSP, or is it Alzheimer’s Disease?”, Neurology Clinical Case Conference

Dec 12, 1991 “Current and Experimental Therapies in AD”, Neurology Noon Conference

Jul 9, 1991 “Geriatric Neurology”, Hartford Foundation Medical Student Fellowship Seminar

May 15, 1991 “Treatment of Dementia and Alzheimer’s Disease”, Division of Geriatric Medicine Clinical Conference

May 16, 1991 “Alzheimer’s Disease or Do You Believe the MRI Scan?”, Neurology Clinical Case Conference

Apr 9, 1991 “Dementia”, Neural and Behavioral Sciences 600 (Constance J. D’Amato, Course Director) (2 hours)

Apr 10, 1991 “Pathophysiology of Dementia,” Division of Geriatric Medicine Clinical Conference

Mar 12, 1991 “Pathophysiology of Headache”, Neural and Behavioral Sciences 600 (Constance J. D’Amato, Course Director)

Feb 20, 1991 “Recognition and Evaluation of Dementia”, Division of Geriatric Medicine Clinical Conference

Jul 19, 1990 “Orientation to Cognitive Disorders Clinic”, Clinical Neurology Conference

Jul 31, 1990 “Geriatric Neurology - An Overview”, Hartford Foundation Medical Student Fellowship Seminar

May 14, 1990 “Uses of PET Scanning in Identifying Different Types of Dementia”, Behavioral Neurology Seminar

Apr 3 & 5, 1990 “Dementia”, Neural and Behavioral Sciences 600 (Constance J. D’Amato, Course Director) (2 hours)

Mar 15, 1990 “Pathophysiology of Headache”, Neural and Behavioral Sciences 600 (Constance J. D’Amato, Course Director) (2 hours)

Feb 22, 1990 “Established and Experimental Therapies for Dementia”, Neurology Clinical Conference

Jan 11, 1990 “Established and Experimental Therapies for Dementia”, Division of Geriatric Medicine Clinical Conference

Jan 12, 1990 “New Strategies for the Treatment of Alzheimer’s Disease”, Michigan ADRC General Meeting

Jan 22, 1990 “A Practical Approach to the Demented Patient”, Medicine Noon Conference

Jul 13, 1989 “Orientation to Cognitive Disorders Clinic”, Clinical Neurology Conference

Apr 4, 1989 “Dementia”, Neural and Behavioral Sciences 600 (Constance J. D’Amato, Course Director) (1 hour)

Feb 23, 1989 “Neuropsychological Tests and Dementia”, Clinical Neurology Conference

Jan 11, 1989 “Therapeutic Approaches to Alzheimer’s Disease”, Pharmacology and Therapeutics LA2U6E (Margaret Gnegy, Ph. D., course director)

Sep 19, 1988 “Case Presentation. Dementia in a Patient with an Unsuspected Brain Tumor”, Turner Clinic Noon Conference

Mar 8, 1988 “Cholinergic Mechanisms of Dementia: Revised Proposal”, PET Users Conference

Mar 28, 1988 “Neurobiology of Growth Factors and Their Therapeutic Potential”, Discussion Panel Symposium, Ann Arbor, MI

Mar 30, 1988 “Dementia, Aging, and Brain Degeneration”, Neuroscience 731 (George J. Siegel, M. D., course director)

Jan 11, 1988 “Evaluation of Dementia -- When, Why and How”, Turner Clinic Noon Conference

Dec 14, 1987 “Cholinergic Mechanisms of Dementia: A Proposal”, PET Users Conference

Sep 21, 1987 “Dementia”, Neural and Behavioral Sciences 600 (Charles B. Smith, M. D., Ph. D., course director) (2 hrs)

Sep 28, 1987 “Headache”, Neural and Behavioral Sciences 600 (Charles B. Smith, M. D., Ph. D., course director) (2 hrs)

Aug 26, 1987 “Cholinergic Agonist Therapy of Progressive Supranuclear Palsy”, CRC Research Seminar

Jul 10, 1987 “Clinical Trials in Movement Disorders”, Guest Rounds, CRC

Mar 23, 1987 “Cholinergic Agonist Therapy of Progressive Supranuclear Palsy”, CRC Research Seminar

Feb 9, 1987 “Parietal Lobe Syndromes”, Clinical Neurology Conference

Feb 16, 1987 “When and Why to Evaluate Dementia”, Medicine Noon Conference

Dec 8, 1986 “When and Why to Evaluate Suspected Dementia”, Clinical Neurology Conference

Dec 15, 1986 “Organic Brain Syndrome”, Clinical Neurology Conference

Oct 16, 1986 “What We Have Learned About Dementia From Positron Emission Tomography”, Neuropsychology and Behavioral Medicine Seminar

Sep 5, 1986 “Dementia -- Recognition and Evaluation”, Neural and Behavioral Sciences 600 (Charles B. Smith, M. D., Ph. D., course director)

Sep 8, 1986 “Dementia -- Alzheimer’s Disease”, Neural and Behavioral Sciences 600 (Charles B. Smith, M. D., Ph. D., course director)

Sep 8, 1986 “Dementia -- Treatment”, Neural and Behavioral Sciences 600 (Charles B. Smith, M. D., Ph. D., course director)

Sep 15, 1986 “Update on PET Studies of Alzheimer’s Disease and Progressive Supranuclear Palsy”, PET Users Conference

Sep 17, 1986 “Pathophysiology of Headache”, Neural and Behavioral Sciences 600 (Charles B. Smith, M. D., Ph. D., course director) (2 hrs)

Dec 16, 1985 “Somatization Disorder and Conversion”, Neurology Clinical Conference

Dec 16, 1985 “Comparison of Alzheimer’s Disease and PSP using F-18 FDG PET”, PET Users Conference

Oct 9, 1985 “Headache”, Neural and Behavioral Sciences 600 (Charles B. Smith, M. D., Ph. D., course director)

Sep 4, 1985 “Effect of Diazepam on FDG-PET in Alzheimer’s Disease”, CRC Research Seminar

Sep 6, 1985 “Dementia”, Neural and Behavioral Sciences 600 (Charles B. Smith, M. D., Ph. D., course director)

Sep 9, 1985 “Alzheimer’s Disease”, Neural and Behavioral Sciences 600 (Charles B. Smith, M. D., Ph. D., course director)

Aug 14, 1985 “Approach to the Patient with Altered Mental Status”, Neurology Clinical Conference

Apr 26, 1985 “Movement Disorders, Dementia, and Brain Imaging”, Dental Neurosciences 503 (Pamela Raymond, Ph. D., course director)

Feb 14, 1985 “Clinical Aspects of Dementia”, Clinical Neuroscience 730 (George J. Siegel, M. D., course director)

Jan 28, 1985 “Pharmacological Treatment of Movement Disorders”, Pharmacology and Therapeutics LA2U6E (Edward Domino, M. D., course director)

Jan 28, 1985 “Treatment of Dementia”, Pharmacology and Therapeutics LA2U6E (Edward Domino, M. D., course director)

Dec 3, 1984 “Evaluation of Dementia in the Cognitive Disorders Clinic”, Turner Clinic Noon Conference

Oct 22, 1984 “Arterial vs. Arterialized Venous Sampling for PET”, PET Users Conference

Sep 12, 1984 “The Use and Interpretation of Psychometric Testing”, Neurology Clinical Conference

Aug 8, 1984 “Current Concepts of Alzheimer’s Disease”, Internal Medicine Noon Conference

COMMUNITY PRESENTATIONS

Nov 16, 2006 Lecturer, The University of Utah President’s Club Luncheon, Ft. Douglas Officer’s Club (Salt Lake City, UT)

Nov 15, 2006 Lecturer, The University of Utah Communications Council (Salt Lake City, UT)

Apr 21, 2006 Panelist, “The Brain Institute: Why? Because We Need One”, Education and Enrichment Session, Discover U Days, University of Utah (Salt Lake City, UT).

Apr 19, 2006 Remarks: “Center for Alzheimer’s Care”, Roundtable discussion: “Collaborative Research”, Utah Commission on Aging Meeting at the University of Utah (Salt Lake City, UT).

Apr 18, 2006 “Meeting the Challenges of Alzheimer’s Care”, The 19th Annual Conference for Seniors: New Visions on Aging, Hosted by Senator Orrin and Mrs. Elaine Hatch, Little America Hotel (Salt Lake City, UT).

Apr 6, 2006 “Early Recognition and Initial Interventions for Alzheimer’s Disease and Related Disorders”, Generations Conference: Behavioral / Mental Health & Substance Abuse Treatment for Adult Generations (Salt Lake City, UT).

Mar 18, 2006 “Current Advances in Brain Research”, AARP Staying Sharp Conference: Current Advances in Brain Research, Provo Marriott (Provo, UT).

Mar 14, 2006 “Understanding Memory Loss, Prognosis, Medications, Associated Psychological Problems and Research”, Early Stage Educational Program, Alzheimer’s Association Utah Chapter (Salt Lake City, UT).

Feb 9, 2006 “A New View of Alzheimer’s Disease: Using Advanced Technology to Improve Patient Care”, Women Investing in Science and Health (WISH) Luncheon, University Hospital Foundation, University of Utah (Salt Lake City, UT).

Jan 24, 2006 Lecture, University of Utah Sugarhouse Clinic (Salt Lake City, UT).

Nov 18, 2005 Remarks, Alzheimer’s Association Remembrance Day Ceremony, Myriad Genetics, University of Utah Research Park (Salt Lake City, UT).

Jun 11, 2003 "Research Advances and Treatment Options”. Great Lakes Chapter, Alzheimer’s Association Annual Meeting (Ann Arbor, MI).

Mar 24, 2001 “Research Update”, Research Retreat, Medical and Scientific Advisory Board, Detroit Area Chapter, Alzheimer’s Association.

May 16, 2001 “Update on Alzheimer’s Disease Research”. 20th Anniversary Celebration and Volunteer Recognition Program, South Central Michigan Chapter, Alzheimer’s Association (Ann Arbor, MI).

Apr 5, 2000 “Early Recognition and Initial Assessment of Dementia” and “Current and Future Prospects for Treating Alzheimer's Disease”, Physician Outreach Conference, East Central Michigan Chapter, Alzheimer’s Association (Flushing, MI).

Nov 12, 1999 “How to Tell When Alzheimer’s Begins and What to Do About It”, Ask the Doctor Series, University of Michigan Geriatric Center (Ann Arbor, MI).

Oct 4, 1999 Testimony, Long Term Care Work Group, Public Hearing (Ann Arbor, MI).

Jan 12, 1999 “Alzheimer's Disease and Dementia: Effective Treatments Today”, Lunch & Learn Series.

Sep 16, 1998 “How to Talk to Patients and Their Families about Autopsy” Michigan Dementia Network Conference (East Lansing, MI).

May 7-8, 1998 "Understanding the Causes of Incapacity: Dementia" and "Clarifying the Role of Surrogate Decision-Making in Mental Health Treatment", I and Thou: Surrogate Decision-Making in the New Millennium, Senior Justice Section, State Bar of Michigan, Washtenaw Community College (Ann Arbor, MI)

Feb 6, 1998 "An Update on Dementia in Michigan", Strengthening our Commitment to Quality Dementia Care, Bureau of Health Systems, Michigan Department of Consumer and Industry Services (Lansing, MI).

Oct 16, 1997 “Can We Prevent Alzheimer's Disease?”, Ask the Doctor Series, University of Michigan Geriatric Center (Ann Arbor, MI).

Aug 21, 1997 “Update on Alzheimer's Disease”, Alzheimer's Association Support Group, Town Center Senior Apartments (Ypsilanti, MI.

Jun 28, 1997 “Update on Alzheimer's Disease Research”, Geriatrics Center Welcome Health Fair.

May 13, 1997 “The Brain”, Miss Everett's Fifth Grade, Burns Park Elementary School (Ann Arbor, MI).

Mar 22, 1997 “Medications and Current Research”, Caregivers Education Series (Saginaw, MI).

Mar 5, 1997 “Update on Alzheimer's Disease”, Saginaw Dementia Services Advisory Committee (Saginaw, MI).

Nov 26, 1996 Keynote speaker: “Alzheimer's Disease Update: Genetics in Alzheimer's Disease”, 8th Annual Meeting of the Southwest Michigan Chapter, Alzheimer's Association, Lawrence Education Center, Borgess Hospital (Kalamazoo, MI).

Nov 6, 1996 “Introduction to Dementia and AD”, Pfizer Drug Representatives, Dearborn Marriott (Dearborn, MI).

Oct 20, 1995 “Overview of Dementia”, Eastern Michigan University (Ypsilanti, MI).

Apr 19, 1995 “Alzheimer’s: Issues and Answers for Those Who Care” and “Overview of Alzheimer’s Disease”, Community Outreach Education Project Conference (Gladwin, MI).

Apr 18, 1995 “Alzheimer’s: Issues and Answers for Those Who Care”, “Overview of Alzheimer’s Disease” and “New Frontiers in Alzheimer’s Disease”, Community Outreach Education Project Conference (Midland, MI).

Nov 30, 1994 “Genetics of Alzheimer’s Disease”, Annual Meeting South Central Michigan Chapter, Alzheimer Association (Ann Arbor, MI).

Nov 18, 1994 “Medical Overview”, Coping with Alzheimer’s Disease in the African-American Community, 2nd Baptist Church (Ypsilanti, MI).

Jun 11, 1994 “Treatment for Alzheimer’s Disease”, Alzheimer’s Caregiver Day, Kellogg Auditorium, Turner Geriatric Clinic (Ann Arbor, MI).

Mar 8, 1994 “What’s Happening in Alzheimer’s Disease”, Senior Workshop, Turner Geriatric Clinic and South Central Chapter, Alzheimer Association.

Mar 23, 1993 “Diagnosis as a Key to Individualizing Care for Those with Dementia”, presented as part of Key Elements in Developing and Designing a Dementia Specific Program, Catherine McAuley Medical Center (Ypsilanti, MI).

Mar 10, 1993 “Michigan Alzheimer’s Disease Research Center”, University of Michigan Hospitals Executive Board (Ann Arbor, MI).

Mar 10, 1993 “Update on the Michigan Alzheimer’s Disease Research Center”, Medical and Scientific Advisory Board, Detroit Area Chapter, Alzheimer Association.

Nov 24, 1992 “PET Scanning: It’s Contributions to Neuroscience Research”, Sangamon County (Illinois) Chapter, Society for Neuroscience.

Feb 5, 1992 “Alzheimer’s Disease and Geriatrics: New Challenges, New Opportunities”, Medical Center Alumni Association (Dallas, TX).

Feb 4, 1992 “Alzheimer’s Disease and Geriatrics: New Challenges, New Opportunities”, Medical Center Alumni Association (Houston, TX).

Nov 6, 1991 “Current Research/Importance of Autopsy”, Conference for Postmortem Network Liaisons, Governor’s Inn Conference Center (Lansing, MI).

Oct 23, 1991 “Let’s Talk About Alzheimer’s,” Peer Counselors of Turner Clinic Social Services Department.

Sep 24, 1991 “Dementia and Its Treatment,” Michigan Coalition for Aging, Lansing, MI.

Jul 23, 1991 “Community Needs for the Patient with dementia,” meeting with community leaders, Northern Michigan Hospital (Petoskey, MI).

Jul 22, 1991 “Dementia - Recognition, Evaluation and Management”, meeting with community health care professionals (Traverse City, MI).

Jul 22, 1991 “Community Needs for the Patient with Dementia”, meeting with health services administrators and executive board of the Northwest Michigan Chapter of the Alzheimer’s Association (Traverse City, MI).

Jul 22, 1991 “New Hope, New challenges in Alzheimer’s Disease Research,” sponsored by the Northwest Michigan Chapter of the Alzheimer’s Association (Traverse City, MI).

May 2, 1991 “Alzheimer’s Disease: New Hope, New Challenges”, Golden K Club (Jacksonville, IL).

May 2, 1991 Invited Lecturer: “Alzheimer’s Disease: The Triumph of the Scientific Method”, MacMurray College (Jacksonville, IL).

Nov 3, 1990 “Alzheimer’s Research in the 90’s”, part of “Help and Hope: A Workshop for Alzheimer’s Caregivers”, sponsored by the South Central Michigan Alzheimer’s Association (Ann Arbor, MI).

Oct 29, 1990 “Research, Training and Clinical Care in Geriatrics at the University of Michigan”, Medical Center Alumni Association (Phoenix, AZ).

Jul 21, 1990 “Outreach Team Training in Dementia: Our Experience and Future Plans”, Michigan Council, Alzheimer’s Association (Ann Arbor, MI).

Jul 11, 1989 “Alzheimer’s disease and related conditions: Current research and treatment”, Michigan Department of Mental Health Seminar for Dementia Model Project and Caregiving Training Project staffs (Lansing, MI).

Apr 25, 1989 “Memory loss: What is normal and what is Alzheimer’s Disease”, Health Night Out Program (Ann Arbor, MI).

Sep 23, 1988 “Overview of Alzheimer’s disease and related disorders”, Child and Family Service of Washtenaw and Area Agency on Aging 1-B Workshop (Ann Arbor, MI).

Jul 18, 1988 “Recent Advances in Alzheimer’s Disease Research”, Alzheimer’s Disease Support Group, Jackson County Health Department (Jackson, MI).

Mar 23, 1988 “What is Normal Memory Loss and What is Not: Positron Emission Tomography as a Useful Tool in Understanding Memory Loss”, Sigma Xi Lecture Series, General Motors Research Laboratories (Warren, MI).

Dec 15, 1987 “Memory Loss and Aging: What is Normal and What is Not”, Living a Healthy Life, Turner Geriatric Clinic (Ann Arbor, MI).

Nov 11, 1987 “Recent Research Trends in Alzheimer’s Disease”, Annual Meeting Lecture, Ann Arbor Area ADRDA (Ann Arbor, MI).

May 19, 1987 “Recent Research in Alzheimer’s Disease”, Support Group Leaders, ADRDA, Greater Ann Arbor Chapter (Ann Arbor, MI).

Jun 18, 1986 “Why Memory Loss Should be Medically Evaluated”, Caring for an Aging Relative Group, Turner Geriatric Clinic

Feb 17, 1986 “Dementia”, Noon Medical Conference, St. Joseph Mercy Hospital (Ann Arbor, MI).

Jan 17, 1985 Speaker: “Alzheimer’s Disease”, For Men Only. Turner Geriatric Clinic.